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ABSTRACT 
 Periodontitis is a highly prevalent chronic inflammatory oral disease. Hyaluronan 
(HA) is a non-sulfated glycosaminoglycan which helps anti-inflammatory and tissue 
repair. The aim of this study was to delineate the effects of various sized HA 
molecules on periodontal cells. Oligosaccharide nano HA and 150 kDA HA were 
used to stimulate human mesenchymal stem cells (hMSCs) and human periodontal 
ligament cells with human telomerase reverse transcriptase (PDLhTERTs), for 3, 7 
and 21 days. HA receptors, CD44, receptor of hyaluronic acid mediated motility 
(CD168) and the Toll-like receptor (TLR)-4, have been substantially expressed in 
both cell types. In hMSCs CD44 and CD168 expression remained roughly unchanged 
during the entire observation period; in PDLhTERTs nano and/or the 150 kDa HA 
fragment significantly attenuated the expression of the CD44 and CD168 receptors. 
TLR4 expression was inhibited by nano and/or 150kDa HA in both cell types at day 
21. The presence of HA reduced the transcription of the cementogenic markers, 
cementum-derived attachment protein (CAP) and cementum protein 1 (CEMP1), in 
both cell types, especially nano HA. Scleraxis (SCX), a ligamentogenic marker, 
remained almost unchanged irrespective of the specific stimulation condition. Early 
stage osteogenic marker alkaline phosphatase (ALP) was induced by the various 
stimulation conditions in both hMSCs and PDLhTERTs and stronger in the presence 
of nano and 150 kDa HA. Bone sialoprotein (BSP) remained roughly unchanged 
under stimulation. Osteogenic markers collagen type I alpha 1 (COL1A1) in both cell 
types and osteocalcin (OCN) in hMSCs were also enhanced by the HA fragments. 
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However in PDLhTERTs OCN was inhibited by 150k HA. The osteogenic 
stimulation alone and together with HA lead to the highest calcium deposition.  
  Taken together the current study revealed that small HA fragments cause 
differential effects on hMSCs and PDLhTERTs. Nano HA seemed to have more 
positive effects in osteogenic differentiation than 150kDa HA. These fragments seem 
to enhance the earlier steps of osteogenic differentiation in both types of stem cells 
but impair the expression of cementogenic differentiation markers and the 
mineralization of the ECM during osteogenesis within 21 days. Since the expression 
of scleraxis was unaffected HA seems to have no influence on the ligamentogenesis. 	
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1. Introduction 
  Periodontitis is a highly prevalent chronic inflammatory oral disease which not only 
leads to bone loss, attachment loss, and tooth loss but also has negative effects for the 
whole body (Hajishengallis 2015). To cure periodontitis, achieve periodontal 
regeneration, needs to reconstruct alveolar bone, connective tissue, cementum and 
periodontal ligament (PDL). Hyaluronan (HA) has influence on tissue repair and has 
already been widely used in medical applications (Tolg et al. 2014, Robert 2015). 
This study aimed to delineate the effects of various sized HA molecules on human 
periodontal ligament cells (PDL-hTERT) and mesenchymal stem cells (hMSCs) 
regeneration. 
 
1.1 HA 
  HA, also called hyaluronic acid, is a non-sulfated glycosaminoglycan. Karl Meyer 
isolated it from vitreous humor first time in 1934 (Meyer et al. 1934). HA can be 
found in all tissue of vertebrates, especially in extracellular matrix (ECM) of skin and 
connective tissues (Laurent et al. 1992, Fraser et al. 1997).  
 
1.2 HMW-HA and LMW-HA 
  The molecular weight of HA shows considerable variability. Native HA exists as 
high-molecular weight HA (HMW-HA) and its typical molecular weight is >106 Da 
(Noble 2002). In addition, low molecular weight HA (LMW-HA) fragments are 
generated as a result of enzymatic activity during HA synthesis or degradation 
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mediated by hyaluronidases or chemical activity triggered by reactive oxygen species 
(Jiang et al. 2007, Kavasi et al. 2017). Enzymatic fragmentation of HMW-HA is 
particularly controlled by hyaluronidase-1 and -2 (Hyal-1 and -2). The membrane 
bound Hyal-2 splices hyaluronan to fragments of 20 kDa. Following endocytosis 
these fragments are subjected to further lysosomal digestion by Hyal-1 (Litwiniuk et 
al. 2016). Commonly the LMW-HA fragments show a highly disperse molecular size 
with overlapping lengths ranging from small oligosaccharides (4mer) to < 500.000 Da 
(Petrey et al. 2014). Depending on the molecular weight HA has different and 
partially antagonistic biological effects (Stern et al. 2006). High molecular weight HA 
promotes tissue homeostasis and inhibits angiogenesis, shows anti-inflammatory and 
immunosuppressive properties and inhibits the proliferation of many cell types (Gao 
et al. 2010, Ghosh et al. 2015). On the contrary low molecular weight HA has been 
suggested to act as danger signal within damaged tissues (Powell et al. 2005). Once 
the tissue homeostasis is disrupted, e.g. upon inflammation, tissue injury and tumor 
invasion the native HMW-HA is degraded into smaller fragments. Both, the loss of 
native HMW-HA and the increasing amount of low molecular weight HA can induce 
changes in cell behavior and signaling (Yang et al. 2012). It has been shown in several 
experimental models that LMW-HA has mitogenic effects and enhances cell 
proliferation (David-Raoudi et al. 2008). Compared to HMW-HA the smaller HA 
fragments exert potent pro-inflammatory and immunostimulatory effects (Wang et al. 
2011, Litwiniuk et al. 2016). Specifically, the very small oligosaccharides seem to 
amplify the signals induced by the presence of small to intermediate-sized fragments 
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of HA (Aya et al. 2014).  
  Due to the effects on cell proliferation and its almost ubiquitous occurrence, HA at 
different molecular weights has been proposed to play a significant role in healing of 
damaged tissue (Jiang et al. 2007, Tolg et al. 2014). Considering the cellular and 
molecular mechanisms involved in wound healing HA induces different effects 
depending on its molecular size (Kavasi et al. 2017). The concentration of HMW-HA 
sharply increases during the earliest phase of wound healing which is degraded 
afterwards leading to the accumulation of LMW-HA. Apart from the induction and 
enhancement of inflammatory reactions functional significance of the HA turnover 
might comprise the stimulation of keratinocytes and fibroblasts during wound healing 
(Tolg et al. 2014, D'Agostino et al. 2015). In intervertebral disc cells specifically HA 
oligosaccharides up regulated various matrix repair genes, i.e. ACAN, COL1A1 and 
COL2A1 (Fuller et al. 2016). Inline with that, the presence of 6mer and 8mer 
oligosaccharides induces a considerably stronger migration of rat dermal fibroblasts 
resulting in a more rapid closure of experimental excision wounds as compared to 
larger HA fragments of 40 kDa (Tolg et al. 2014).   
 
1.3 HA receptors 
   HA has many receptors, including CD44, CD168, Toll-like receptor 4 (TLR4)，
Toll-like receptor-2 (TLR2)，intercellular adhesion molecule-1 (ICAM-1), Lymphatic 
Vessel Endothelial hyaluronan receptor 1 (LYVE 1) and so on (Vigetti et al. 2014). 
CD44 and CD168 are related with cell proliferation, migration and tumorigenesis. 
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TLR2 and TLR 4 are related with inflammation, cell survival and apoptosis. CD44, 
CD168 and TLR4 are relative to wound healing, infection and tissue recognition, 
therefore they were chosen to be tested in this research. 
 
1.3.1 CD44 
  CD44 is the main receptor for the perception and mediation of the HA signal 
(Wang et al. 2011, Yang et al. 2012). As a result of alternative splicing and 
post-translational modifications it occurs in various isoforms in the membrane of 
many human cells showing different affinity for HA (Aruffo et al. 1990, Tammi et al. 
1998). CD44 is not only important for the interactions between cells and the ECM but 
also for the intercellular interactions (Bajorath 2000). It was shown that CD44 is 
highly expressed in the dermal and epithelial compartment of the human skin (Wang 
et al. 1992). In keratinocytes the CD44 receptor seems to mediate various central 
functions in maintaining tissue homeostasis and repair, i.e. binding to growth factors 
and intercellular adhesion (Bourguignon 2014, Kavasi et al. 2017). Moreover, the 
CD44 receptor seems to be involved in the HA induced differentiation of monocytes 
into fibrocytes during wound repair (Maharjan et al. 2011).  
 
1.3.2 CD168 
  CD168, also named RHAMM (receptor for hyaluronan-mediated motility), is the 
second major HA receptor that is present in numerous cell types (Entwistle et al. 
1996, Croce et al. 2003). CD168 contributes to fibroblast migration, differentiation
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and wound repair (Tolg et al. 2006). HA requires CD168 in modulating growth factor 
induced mammary gland branching (Tolg et al. 2017). Compared with benign tissues, 
malignant tumors have higher HA deposition. HA predicts tumor progression in some 
tumor types and affects tumorigenesis and tumor aggressiveness (Nikitovic et al. 
2013, Vigetti et al. 2014). CD168 regulates LMW-HA via a beta-catenin/c-myc 
signaling axis and, for example, suppresses fibrosarcoma cell proliferation (Kouvidi et 
al. 2016). 
 
1.3.3 TLR-4 
  In the ECM of injured or inflamed tissue LMW-HA will be broken down into low 
molecular weight fragments, which can stimulate epithelial cells and promote injury 
recognition through TLR4 (Taylor et al. 2004, Jiang et al. 2005). Though CD44 is the 
main receptor of HA, it is not required for HA to stimulate pro-inflammatory 
chemokines through TLRs. A study of lung injury showed that, in CD44-null mice 
LMW-HA can induce skin self-defense to protect cutaneous tissue from infection 
through release of β-defensin 2 by mediation of TLR2 and TLR4 (Gariboldi et al. 
2008). Compared with TLR2, TLR4 can recognize lipopolysaccharide (LPS) pattern 
better (Takeuchi et al. 1999, Park et al. 2013, Mukherjee et al. 2016). LPS pattern is 
one of the progenitors to periodontitis (Dumitrescu et al. 2004), the most popular oral 
disease which leads to periodontal damage. This study aims to figure out HA’s effect 
on inflamed periodontal regeneration, therefore TLR4 was chosen in this research. 
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1.4 Cells, markers and periodontal regeneration 
 Periodontal cells human mesenchymal stem cell (hMSC) and human periodontal 
ligament cells with human telomerase reverse transcriptase (PDLhTERTs) were 
chosen in this research. 
 
1.4.1 hMSC 
  hMSCs exist extensively in all human tissues. They are mostly found in adult bone 
marrow (Caplan 1991, Bianco 2014), and, among others, can also be found in tooth 
pulp and periodontal tissues (Gronthos et al. 2000, Egusa et al. 2012). They are 
multipotential cells and can regenerate to several kinds of tissues such as bone, 
tendon, cartilage, ligament, muscle, endothelium, and epithelial cells (Pittenger et al. 
1999, Jiang et al. 2002, Reyes et al. 2002). hMSCs can also produce growth factors 
and various cytokines, for instance bone morphogenetic protein (BMP) and 
transforming growth factor β 1 (TGF-β1), which can induce bone, cartilage, and 
tendon repair (Nixon et al. 2007, Borakati et al. 2018). Moreover, they are low 
immunogenicity cells that can be tolerated by the immune system and will home and 
migrate to damaged tissues when injured or inflamed (Rasmusson et al. 2007, 
Rasmusson et al. 2007, Rustad et al. 2012). Conclusively, MSCs are able to 
regenerate periodontal tissues and MSCs stem-cell-based therapy are widely used in 
several clinical disciplines (Egusa et al. 2012, Monsarrat et al. 2014).   
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1.4.2 PDLhTERT 
  PDLhTERTs are a periodontal ligament cell (PDL) derived immortalized cell line. 
They were transferred with lentivirus human telomerase reverse transcriptase 
(hTERT) and share the same characteristic as primary PDL cells (Docheva et al. 2010, 
Zhu et al. 2015). PDLhTERTs are hMSC-like cells since they can express some 
hMSC markers. They can also differentiate into osteoblasts, cementoblasts, 
adipocytes, and chondrocytes. Moreover, they can express osteoblast-related genes 
such as alkaline phosphatase (ALP), bone sialoprotein (BSP), collagen, osteocalcin 
(OCN) and they can also promote periodontal regeneration (Mizuno et al. 2001, Seo 
et al. 2004, Huang et al. 2009, Wada et al. 2009, Docheva et al. 2010). PDLhTERTs 
can also express tendon related gene scleraxis (SCX) (Docheva et al. 2010). 
 
1.4.3 Periodontal regeneration and HA receptors 
  Periodontitis as a highly prevalent oral disease mostly found in adults leads to bone 
loss, attachment loss and ultimately to tooth loss. To achieve periodontal regeneration 
needs to reconstruct alveolar bone, connective tissue, cementum and periodontal 
ligament. Stem cells such as hMSCs and MSC-like PDL cells, which are rich in 
periodontal tissues, are reported to be able to rebuild bone, cementum, collagen, 
ligament and, thus, to contribute to periodontal regeneration (Seo et al. 2004, Egusa et 
al. 2012, Tomokiyo et al. 2012). 
  hMSCs and PDL cells express both CD44 and CD168 receptors (Entwistle et al. 
1996, Bian et al. 2013). It would be interesting to test the different cells, hMSCs and 
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PDL cells, under the stimulation of different molecular weight HA. And these would 
be helpful in making HA treatment a promising strategy for tissue regeneration 
(Ishikawa et al. 2014, Litwiniuk et al. 2016). 
  The proliferation and mineralization of human PDL cells has been shown to be 
linked to the expression of the CD44 receptor (Yeh et al. 2014). Several studies have 
found elevated levels of HA fragments in the gingival crevicular fluid at periodontally 
affected sites depending on the inflammatory activity (Utoh et al. 1998, Yan et al. 
2000). Since the gingival crevicular fluid comprises a transudate or exudate of the 
blood serum and due to the inflammatory condition at periodontal affected sites the 
GCF contains considerable amounts of low molecular weight HA (Nakatani et al. 
2009). Taken together, it seems plausible that these HA fragments at inflamed 
periodontal sites might interfere with the healing and regenerative capacity of 
periodontal tissues.  
  
1.4.4 Cementogenic marker CAP and CEMP1 
  Periodontal attachment recover is primary for periodontal regeneration.  
Cementum protein 1 (CEMP1), as well as cementum attachment protein (CAP) are 
periodontal attachment related markers (Arzate et al. 2015). CEMP1 can induce 
cementoblasts phenotype and reduce osteoblast differentiation in PDL (Komaki et al. 
2012). Both, normal human PDL cells and human immortal PDL-derived cell lines 
can express CAP and CEMP1 and have cementogenic potential (Torii et al. 2015). 
hMSCs, as mesenchymal stem cells, also have been proposed to have cementogenic 
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potential. However osteogenic stimulation seem to inhibit CAP and CEMP1 
expression of PDL cells. On the contrary the presence of vitamin C (VC) can reverse 
this inhibitory effect and enhance cementogenic differentiation (Gauthier et al. 2017).   
  GAGs, especially HA, exist in cementum-dentin junction (CDJ) and were found 
important for cementum formation and mineralization (Cheng et al. 1999, Yamamoto 
et al. 2004, Ho et al. 2005). HA/CD44 pathway was found essential for fibroblast 
growth factor 2 (FGF2) in PDL cells migration (Shimabukuro et al. 2011). FGF2 
induced PDL stem cells into ligamentogenic differentiation but suppress osteogenic 
and cementogenic differentiation (Hyun et al. 2017). It would be interesting to see if 
HA can stimulate whether osteogenesis and cementogenesis or ligamentogenesis. 
 
1.4.5 Osteogenic and ligamentogenic markers 
  Alveolar bone recognition is a symbol of periodontitis convalescence. Osteoblasts 
secrete matrix proteins and format new bone. Therefore, osteoblast-related markers 
ALP, BSP, collagen type I alpha 1 (COL1A1) and OCN were chosen in this study 
(Weinreb et al. 1990, Karsenty et al. 1995).  
  ALP, BSP and COL1A1 were reported as early stage markers of osteoblastic 
differentiation while OCN is a late stage marker (Weinreb et al. 1990, Kuo et al. 
2017). The up regulation of ALP expression reflected the rate of hMSCs committed 
differentiation (Jaiswal et al. 1997, Kuo et al. 2017). BSP is a phosphorylated 
glycoprotein which contributes to bone, dentin, cementum mineralization. It also has 
angiogenic capacity and gathers near primary bone (Fisher et al. 1990, Ogata 2008, 
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Bouleftour et al. 2016). ALP and BSP expressions were different among various 
donors of hMSCs (Phinney et al. 1999). For human PDL cells, ALP expression was 
measurable by 14th day of osteogenic culture while human bone marrow stem cells 
(hBMSCs) by 7th day; BSP expression was measurable both in human PDL cells and 
hBMSCs by 7th day. At day 21, collagen II and glycosaminoglycans was detected in 
both cells under chondrogenic induction (Gay et al. 2007). 
  Type I collagen is abundant in the matrix of bone, dermis, tendons and is 
synthesized by both osteoblast and fibroblast. COL1A1 is the most produced 
polypeptide chains of type I collagen so it was chosen in this research (Karsenty et al. 
1995, Ghosh 2002). OCN is a small protein produced by osteoblast, odontoblasts and 
hypertrophic chondrocytes. It is correlated with bone mineralization, metabolism and 
formation (Hauschka et al. 1989, Lee et al. 2007). hBMSCs’ osteogenic 
differentiation was improved by HA hydrogel, manifested as increased ALP, OCN, 
COL1A1 expressions and calcium contents (Jung et al. 2018). 
  Scleraxis (SCX) is the ligamentogenic marker produced mostly by osteoblast and is 
essential in tendon wound healing (Sakabe et al. 2018). PDL stem cells were reported 
to be able to express certain amount of SCX like keratinocytes. The same for 
COL1A1 expression (Chen et al. 2018). hMSCs, as multipotent cells, can also express 
SCX and develop tenogenic differentiation. SCX played an essential part in tendon 
differentiation progenitor of hMSCs (Alberton et al. 2012).  
  Former studies indicate that HMW-HA can increase proliferation and COL1A1 
expression of human rotator cuff tendon derived cells (Osti et al. 2015). What HA will 
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militate PDL cells and hMSCs remains subject of further research.  
 
  In general, HA is rich in ECM and takes part in many cellular activities such as cell 
migration, proliferation and differentiation. HA also contributes to anti-inflammation, 
wound healing and can be used in osteoarthritis, cartilage repair, tendon healing, 
annulus fibrous defect, and skin repair (Wang et al. 2007, Ryan et al. 2015, Fuller et 
al. 2016, Ferrero et al. 2018, Piuzzi et al. 2018). How HA may affect periodontal cells 
yet remains unclear. It would be very interesting to see if HA can be used as a novel 
periodontal regeneration accelerant. To verify this hypothesis, periodontal cells 
hMSCs and PDL cells were chosen. As mentioned above, they both can induce 
osteogenesis, ligamentogenesis and cementogenesis, which means they have 
periodontal regenerative potential. So we used HA to stimulate hMSCs and PDL cells, 
then test osteogenic, ligamentogenic and cementogenic related gene expressions to see 
how HA will promote periodontal regeneration.  
 
1.5 Aim of the study 
  This study aims to figure out whether LMW-HA can promote periodontal 
regeneration. For this purpose, the effects of LMW-HA on the cementogenic, 
ligamentogenic and osteogenic differentiation of periodontal cells (hMSCs and PDL 
cells) were explored.   
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2. Materials and Methods   
2.1 Cell culture 
 
2.1.1 hMSC 
  hMSCs were obtained from Lonza company (Verviers, Belgium), donated by a 
male caucasian and marked as ‘donor VII’. Cell culture medium was α-minimum 
essential medium (α-MEM) (gibco-Thermo Fisher, Waltham, USA), with additive 
10 % Fetal Bovine Serum (FBS) (Sigma Aldrich, Munich, Germany) and 1% 
Penicillin (Sigma Aldrich, Munich, Germany). Because the differentiation potential of 
hMSC will drop from the 6th passage on (Bonab et al. 2006), 5th and 6th passages of 
hMSCs were used in this study. 
 
2.1.2 PDLhTERT 
  PDLhTERTs were obtained from Professor Docheva (University of Regensburg, 
Germany) (Docheva et al. 2010). Culture medium was high glucose-Dulbecco’s 
Modified Eagle Medium (DMEM) (Sigma Aldrich, Munich, Germany), with additive 
10 % FBS and 1% Penicillin. 28th and 29th passages of PDLhTERT cells were used in 
this experiment. 
 
  Both hMSCs and PDLhTERTs were cultured in 37℃, 5% CO2, humid incubator 
(ThermoFisher, Waltham, USA). The culture medium was always pre-warmed to 
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37℃ before use and changed twice a week. Cells in early passage were firstly 
cultured in T75 flasks (Greiner Bio-one, Frickenhausen, Germany), then counted and 
seeded in different cell culture plates or flasks as required. During cell culture, when 
the cells got confluent, they were passed. Cells were incubated in 37℃, 5% CO2, 
humid incubator with trypsin (Merck, Munich, Germany) for 5min, then checked 
under a microscope (Carl Zeiss, Jena, Germany) to see if all the cells were detached. 
When all the cells were detached, the culture medium was added to stop reaction. 
Then cells were counted with hemocytometer (Abcam, Cambridge, GB) and 
centrifuged with 500 rpm for 5 min under room temperature in the centrifugal 
machine (Thermo Fisher, Waltham, USA). The upper liquid were aspirated and then 
cells were diluted with acquired amount of fresh culture medium. They were then 
mixed well and seeded in new flasks.  
 
2.1.3 Osteogenic medium and HA working medium prepare 
  Self-made osteogenic medium (OS), components presented as in Table 1, was used 
to introduce osteogenic differentiation. Dexamethasone, β-Glycerophosphate and 
L-Ascorbic acid (all from Sigma Aldrich, Munich, Germany) were diluted and 
sterilized with 0.2 µm sterile syringe filter (VWR, Radnor, USA) before use. Each 
time the OS medium was freshly made and discarded after 4 weeks. OS medium was 
kept in 4 ℃ fridge and warmed in 37 ℃ water bath before use.  
   To figure out the function of different molecular weight LMW-HA (Stern, Asari et 
al. 2006, Kavasi, Berdiaki et al. 2017), oligosaccharide nano HA (HYALOSE, Austin, 
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USA) and 150kDa HA (HYALOSE, Austin, USA) were chosen. HA powders, 1 mg 
per vial, were obtained from the company HYALOSE. Firstly they were diluted into 1 
mg/ml with Dulbecco’s Phosphate Buffered Saline (DPBS) (sigma-Aldrich, 
Steinheim, Germany). Then they were periodically vibrated in 4 ℃ for 2h to achieve 
complete dissolution. Diluted HA was kept in -20 ℃ fridge. To avoid multiple freeze 
and thaw, HA solution was aliquoted into 100 µl each eppendorf tube (Merck, 
Munich, Germany). Considering the HA concentrations in former studies, the working 
concentration 20 ng/ml was chosen in this study (Kaneko et al. 2015, Zhao et al. 
2015). OS medium or DMEM was firstly warmed in 37 ℃ water bath, then added 
acquired amount of HA solution and mixed well. HA was unsterilized when obtained 
from the manufacturer. Therefore, the working HA medium was filter sterilized with 
0.2 µm sterile syringe filter (VWR, Radnor, USA). Because of the filter loss, each 
time and each group received an extra 0.5ml of working medium. To avoid HA 
degradation, each time working medium was freshly made (Pigman et al. 1961). 
 Table	1	Constitute	of	Osteogenic	medium. 
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Table	1	Constitute	of	Osteogenic	medium. 
Osteogenic medium 	 Total 250ml	
DMEM (Sigma Aldrich, Munich, Germany)	 219.5 ml	
FBS (Sigma Aldrich, Munich, Germany)	 25.0 ml	
Penicillin-Streptomycin (Sigma Aldrich, Munich, Germany)	 2.5 ml	
Dexamethasone (Sigma Aldrich, Munich, Germany)	 0.5 ml	
β-Glycerophosphate (Sigma Aldrich, Munich, Germany)	 1.5 ml	
L-Ascorbic acid (Sigma Aldrich, Munich, Germany)	 1.0 ml	
 
 
 
 
 
 
 
2.2 Flow cytometry analysis 
  PDLhTERTs and hMSCs were divided into 6 groups, PDLhTERT groups: control, 
nano HA and 150k HA; hMSC groups: control, nano HA and 150k HA. Each group 
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was seeded in 2 flasks as duplicates. Cells were stimulated for 7 days (change medium 
twice) then harvested for test. On the 5th day of cell culture, 2 days before the harvest 
day, an extra control group, day 0 was seeded. Cells were detached with Accutase 
(Sigma-Aldrich; 5 min at 37°C) and then incubated (30 min on ice) with the following 
antibodies: mouse anti-human CD44-FITC and CD90-PECy7 (both BioLegend) or 
rabbit anti-human CD168 (Abcam). CD90 is used as a surrogate marker for stem 
cells. A secondary Alexa Fluor 647 donkey anti-rabbit antibody (BioLegend) was 
used for fluorescence detection of CD168. Sample tubes were acquired on a BD 
FACSAria III (BD Biosciences) and 10.000 gated events were recorded. Data were 
analyzed with BD FACSDiva and FlowJo V10 software. 
 
2.3 Immunofluorescence analysis 
  Immunofluorescence is the technique that made antibodies bond to the specific 
epitope of the antigen within the cells visual. CD44, CD168 and TLR4 antibodies 
were chosen in this research. hMSCs and PDLhTERTs were made slides, stained with 
these antibodies and made immunofluorescence images. 
 
2.3.1 Slides preparation 
  hMSCs and PDLhTERTs were divided into 6 groups, hMSC groups: control, nano 
HA and 150k HA; PDLhTERT groups: control, nano HA and 150k HA.  
   Cells were seeded on glass slides (Menzel, Munich, Germany): 0.5ml per slides, 
40,000 cell/ml. Slides were laid into quadrilPERM dishes (Sarstedt, Nümbrecht, 
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Germany) and incubated for 2h in 5% CO2, 37℃ incubator to get the cells attached. 
Slides were then checked under a microscope (Carl Zeiss, Jena, Germany) to ensure 
that all cells were attached. Then 2 ml working medium was added into each dish as 
designed and cells were incubated overnight. On the next day, slides were fixed with 
methanol (Carl Roth, Karlsruhe, Germany) and kept in -20℃ fridge before staining. 
 
2.3.2 Staining with CD44 and CD168 antibodies 
   Before staining, slides were divided into 3 parts with wax pen: control part, 1:50 
and 1:100 dilutions of antibody parts.  
   Firstly, slides were washed 5min with washing buffer: phosphate-buffered saline 
(PBS) (Sigma Aldrich, Munich, Germany) with 1% Tween-20 (Carl Roth, Karlsruhe, 
Germany). Then slides were blocked with 10 % horse serum in dark ( 1 h at room 
temperature). After that, control groups were incubated with PBS; other groups 
incubated with diluted primary antibodies: CD44, CD168 (Santa Cruz, Heidelberg, 
Germany). Then slides were incubated in 4 °C fridge in dark overnight. On the next 
day, the slides were treated with 1:500 AlexaFluor 488 anti-rabbit and anti-goat IgG 
medium (Invitrogen, Eugene, OR, USA) in room temperature for 1 hour, and then 
washed with washing buffer. After that all slides were applied with 4’, 
6-diamidino-2-phenylindole (DAPI) (Invitrogen, Eugene, OR, USA) with 
concentration of 1:10000 for 1min, then washed again. All the solutions used in this 
experiment, such as washing buffer, antibody solutions,  DAPI solution and so on, 
were freshly made. 
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2.3.3 Seal slides with cover glass 
  After staining, all slides were sealed with ProLongTM Gold antifade reagent 
(ProLongTM , Eugene, USA) with 24*50mm cover glass (Menzel, Munich, Germany). 
Bubbles were pressed out until at least working parts of the slides were clear.  Slides 
were then kept in 4℃ in dark. 
 
2.3.4 LSM510 confocal imaging 
  Images were obtained with Laser Scanning Microscope 510 (LSM 510) and 
AxioCam MRc (both Carl Zeiss, Jena, Germany). Confocal channels DAPI and Alexa 
488 were chosen in the program Axio Vision (Carl Zeiss, Jena, Germany). DAPI filter 
was used to obtain the core images of the cells and 44FITC filter to obtain the 
cytoplasm images, both under x63 oil ocular. All the images were obtained within 1 
week after staining.  
 
2.4 Polymerase chain reaction 
  This study aims to figure out the effects of LMW-HA on the cementogenic, 
ligamentogenic and osteogenic differentiation of human hMSCs and PDL-hTERTs. 
To do PCR needs cDNA of the cells and related primers. Cementogenic related 
primers, ligamentogenic related primers and HA related primers were self-designed. 
Osteogenic related primers were acquired from company. They were all proved viable 
with their specific positive controls.  
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  hMSCs and PDL-hTERTs were divided into 6 groups, hMSC groups: control, 
+OS+nano HA and +OS+150k HA; PDLhTERT groups: control, +OS+nano HA and 
+OS+150k HA. They were cultured for 0, 3, 7, 21 days with working medium as 
designed and harvested by different time points. Harvested cells were firstly isolated 
RNA and then transferred into cDNA for PCR tests. 
 
2.4.1 cDNA prepare 
 2.4.1.1 Cell culture and sample harvest 
  hMSCs in the 5th passage and PDLhTERTs in 27th passage were firstly cultured in 
T75 flasks. When they were confluent, cells were treated with trypsin (Merck, 
Munich, Germany). When all the cells were detached, they were added with culture 
medium to stop reaction and then counted. About 1 million hMSCs and PDLhTERTs 
were collected into two separate tubes (Merck, Munich, Germany), which were 
considered as day 0, the starting line. The rest of the cells were seeded in T25 flasks 
and divided into 8 groups, hMSC groups: control; +OS; +OS+nano HA; +OS+150k 
HA; PDLhTERT groups: control; +OS; +OS+nano HA; +OS+150k HA. After 48h, 
when all cells were attached, they were changed with working medium and 
stimulation started. Time points were designed as 3 day, 7 day, and 21 day. 
  Cells of different time points were harvested separately with TRIzol® Reagent 
(Invitrogen, Carlsbad, CA, USA). Firstly the upper liquid of cells were aspired, then 
required amount of TRIzol reagent was added. All the flasks were then put on ice, 
later operations were all done on ice. Cells were scraped (Greiner bio-one, 
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Frickenhausen, Germany) and collected in different labeled tubes (Merck, Munich, 
Germany). Samples were stored in -80℃ fridge for RNA isolation. 
 
 2.4.1.2 RNA isolation 
  Samples with TRIzol reagent were thawed at room temperature. Then chloroform 
(Sigma Aldrich, Munich, Germany) was added (200 µl chloroform for 1ml TRIzol) 
and mixed well. Then all the samples were centrifuged 10,000 rpm for 15 min in a 
centrifuge (Thermo Fisher, Waltham, USA). After centrifugation, liquid was divided 
into different layers. The upper transparent layer was carefully collected into 
RNA-free eppendorf tubes (Merck, Munich, Germany). The volume of the collected 
upper transparent liquids were measured. Same volume of 70% ethyl alcohol (Sigma, 
St. Louis, USA) was added into tubes and mixed gently.  
  RNeasy Mini Kit 250 (Qiagen, Hilden, Germany) was used for RNA isolation. 
Each time a maximum of 700 µl liquid (made last step) was added into the rose tube 
from the kit. Rose tubes were centrifuged 10000 rpm for 15s, then added 350 µl RW1 
and centrifuged again. DNase mix, 10 µl DNase diluted in 70 µl RDD Buffer for each 
sample, was counted and made. DNase and RDD Buffer were obtained from 
RNA-free DNase set 50 (Qiagen, Hilden, Germany). Then 80 µl DNase mix was 
added into each rose tube. Rose tubes were incubated (15 min, room temperature) and 
washed with 350 µl RW1 again. Then 500 µl RPE Buffer was added into each rose 
tubes and centrifuged 10000 rpm for 1min. Until now the liquids after centrifugation 
of all the former steps were discarded. The rose tubes were then changed with new 
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RNA-free 2ml tubes and added 50 µl RNA-free water. Tubes were incubated (1 min, 
room temperature) and then centrifuged 10000 rpm for 1 min. What left in the tubes 
now was sample RNA. 
  All RNA samples were tested with the NanoDrop™ machine (Thermo Fisher, 
Waltham, USA) for optical density A260/A280 ratio. Samples’ inclusion criteria was 
A260/A280 ratio from 1.8 to 2.1. All sample RNA were stored in -80℃ fridge. 
 
2.4.1.3 RNA transferred to cDNA 
  To unify the start line of PCR, cDNA amount of different samples should be the 
same. Thus for each sample the total amount of RNA for cDNA transfer should also 
be the same. Due to biologic differences and other effect factors the concentration of 
isolated RNA were not the same, even in the same group of same cell type. Therefore 
the volume of RNA used should be calculated as following. 
  The total amount of RNA was settled as 500 ng per sample and the total volume of 
each sample (RNA+H2O) was settled as 11 µl. The calculation equation was as 
follows and an example is presented as in Table 2. RNA concentration between 45.5 
(ng/µl) and 500 (ng/µl) can be calculated like this. For those samples with RNA 
concentration lower than 45.5 (ng/µl), they were heated till all water evaporated and 
then diluted to the needed concentration. For those samples with RNA concentration  
over 500 (ng/µl), they were diluted to lower concentrations and then calculated as 
normal. 
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RNA calculation equation: 
 
  500ng RNA needed RNA sample volume (µl) =  500 ng / RNA concentration 
(ng/µl) 
 
    needed H2O (µl) = 11 (µl) - 500ng need RNA (µl) 
 
 Table	2	 	 RNA	calculation. 
Sample 	 RNA	concentration	(ng/µl)	  260/280 260/230 500ng	need	RNA	(µl) need	H2O	(µl) Total	volume	(µl) NO.1 53,31 2,01 1,65 9,38 1,62 11,00 NO.2 141,94 2,05 1,03 3,52 7,48 11,00 
 
 
 
 
 
 
 
  All diluted sample RNA should be denatured before transfer, procedure was as in 
Table 3. When denaturing finished, sample probes were put on ice immediately and 
started RNA transfer to cDNA . All the pipetting work was done on ice with materials 
obtained from first-strand cDNA Synthesis Kit (Roche, Mannheim, Germany), 
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presented in Table 4. Filtered tips were changed every time to avoid contamination. 
  To assure no contamination during transfer procedures, negative controls were 
made. Two extra tubes labeled ‘neg 1’ and ‘neg 2’ were prepared. For these two 
negative controls, PCR grade H2O (SG, Roche, Mannheim, Germany) was used as 
replacement of sample RNA added into probes. Except that, other steps were the same 
as RNA samples. In RNA transfer to cDNA procedure, as showed in Table 4, ‘neg 1’ 
was lack of AMV Reverse Transcriptase and ‘neg 2’ not. Apart from that difference, 
negative controls were handled as other samples.  
 Table	3	 	 Denaturing	procedure. 
Reaction-Mix	
Probe (RNA+ H2O)	 11.0 µl	
Hexamer Primer	 2.0 µl	
Procedure:	  
  1=65℃ for 15min	  
  2=4℃ ∞	  
  3=end  	  
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Then RNA was to cDNA. The procedure was as following.  Table	4	 	 RNA	transfer	to	cDNA	procedure 
Reaction Mix     20.0 µl in total	
Rxnbuffer	 4.0 µl	
dNTPs (10 mM each)	 2.0 µl	
RNAse Inhibitor 40U	 0.5 µl	
AMV Reverse Transcriptase	 0.5 µl	
Probe (RNA+ H2O+ Hexamer Primer)	 13.0 µl	
Procedure:	  
  1=25℃ for 15min	  
  2=50℃ for 60min	  
  3=85℃ for 5min	  
  4=4℃ for 5min	  
  5=4℃ ∞ 	  
  6=end 	  
 
 
 
 
 
 
                           
  cDNA samples, including negative controls (neg1 and neg 2), were stored in -20℃ 
fridge for future PCR test. 
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2.4.2 Self-designed primers 
  Primers: CD44, CD168, TRL-4, CAP, CEMP1, ALP, BSP, COL1A1, OCN, and 
SCX were tested in this research. Of these 10 primers, CD44, CD168, TLR4, CAP 
and CEMP1 were self-designed. SCX sequences was obtained from literature 
(Schulze-Tanzil et al. 2004).  
 
 
2.4.2.1 Primer sequence design 
  Pubmed was used for self-designed primers. For example, inquire ‘Homo sapiens; 
CD44 mRNA’ in Pubmed and a series of primer pairs were obtained, as shown in 
Table 4 and 5. For one primer about 4 different primer pairs were obtained from 
Pubmed gene bank for test. 
  The viability and annealing conditions of these 6 primers were tested by PCR and 
verified in gel electrophoresis. If primer pairs were not working, new primer pairs 
were designed and tested again until viable primer was found. All these primers were 
provided by TIB-MOLBIOL (Berlin, Germany). 
 Table	5	 	 CD44	Primer	pair	1. 
 
Sequence	(5'->3') Template	strand Length Start Stop Tm GC% 
Self	complementarity 
Self	3'	complementarity 
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Table	5	 	 CD44	Primer	pair	1. 
Forward	primer 
AGAAGAAAGCCAGTGCGTCTC Plus 21 2 22 61,08 
52,38 3,00 3,00 
Reverse	primer 
TGCTCTGCTGAGGCTGTAAAT Minus 21 129 109 60,17 
47,62 6,00 2,00 
Product	length 128         
 
 
 
 
 
 
 Table	6	 	 CD44	Primer	pair	2. 
 
Sequence	(5'->3') Template	strand Length Start Stop Tm GC% 
Self	complementarity 
Self	3'	complementarity 
Forward	primer GGCAGCCCCGATTATTTA Plus 18 96 113 58,52 50,00 5,00 2,00 
Reverse	primer 
GCTGCAGTTTTTATTCGAGGT Minus 21 285 265 
58,53 42,86 6,00 0,00 
Product	length 190         
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2.4.2.2 Viability test of self-designed primers, PCR part 
  To verify primer is viable or not needs to test with positive controls. For one primer 
4 possible positive controls were used. PDL and hMSC were used for main purpose of 
this research so they both were chosen as positive controls. Other positive controls 
were found in protein atlas. Positive controls tested for each primer were presented as 
in Table 6. Positive controls were made cDNA and stored in -20℃ fridge for future 
test. 
 
Table 7  Positive control of self-designed primers. 
Primer Positive	control CD44 PDL	cell hMSC Bone Teeth CD168 PDL	cell hMSC Bone Teeth TLR4 PDL	cell hMSC Bone Colon	tissue CAP PDL	cell hMSC Bone Caco-2 CEMP1 PDL	cell hMSC Bone Caco-2 SCX PDL	cell hMSC Bone Tendon 
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   PCR was used to verify primer works with positive control. PCR master mix was 
prepared as follows: A sterile 1.5 ml RNA-free eppendorf tube (Merck, Munich, 
Germany) labeled as ‘master mix’ was prepared. It was then pipetted into appropriate 
amount of primer, H2O, and Syber Green Master I (Roche, Mannheim, Germany) as 
presented in Table 7, then mixed well. 15 µl of the master mix was pipetted into 
RNA-free eppendorf tubes and then 5 µl of positive control cDNAs. When finishing 
pipetting the tubes were mixed well and centrifuged to make sure all liquids were in 
the bottom of the tubes without bubbles. Then the tubes were run in Dyad Peltier 
Thermal Cycler machine (San Diego, USA) under specific thermocycling conditions. 
  The appropriate thermocycling condition, especially annealing temperature of 
self-designed primers were unknown. To figure out the thermocycling conditions of 
these primers, several tests were done. Pubmed gene bank has already provided a 
suggested annealing temperature for each primer pair. We settled the running 
annealing temperature 1 or 2 degrees higher and lower than the suggested annealing 
temperature to find the most appropriate one. For example, the suggested annealing 
temperature of CD44 pair 1 was 60℃, so the testing annealing temperatures of CD44 
pair 1 was 59℃ and 61℃. Then PCR of different annealing temperatures were run in 
PCR, then PCR products were used for gel electrophoresis. Primer pair of the best 
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stain in gel electrophoresis image was chosen. Same procedures were done for all the 
primer pairs with different annealing temperatures. If the normal PCR results were 
unsatisfactory, touch down PCR was  applied. 
 
 
 Table	8	 	 PCR	Master	Mix	and	thermocycling	condition 
Primer  2.0 µl Master Mix: 15.0 µl 
H2O      3.0 µl 
Syber Green I Master 10.0 µl 
PCR Procedure:	
  1=95℃ for 15min	
  2=94℃ for 30sec	
  3=Annealing temperature for 30sec	
  4=72℃ for 60sec	
  5=72℃ for 10min 	
  6=end                                      x  45 cycles	
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2.4.2.3 Viability test of self-designed primers, gel electrophoresis part 
  PCR products were used for gel electrophoresis and then digital images were 
obtained. Depending on the digital images, the most appropriate primer pairs and 
thermocycling conditions were chosen.  
 
 Gel making 
  Gel electrophoresis can be used for analysis of DNA, RNA and proteins by their 
size and charge. First of all an agarose gel was made. 1.8 g agarose (Biozym, Hessisch 
Oldendorf, Germany ) was diluted in 100 ml Tris-borate-EDTA (TBE) buffer 
(Thermo Fisher, Waltham, USA) in a glass bottle. Then 4 µl Ethidium Bromide (EB) 
(Apotheke Klinikum Innenstadt, Munich, Germany) was added into the bottle. 
Because the toxicity of EB, separate EB only instruments and working place were 
required. Operator must wear glove during the whole procedure working with EB. To 
help agarose dilute the whole bottle was heated 3 times in microwave oven shortly. 
When the agarose was completely diluted and no macroscopic bubbles inside, the 
solution was poured into the plate. A comb was inset into the gel quickly. The gel was 
checked carefully to make sure no bubbles were in working part. If there was a 
bubble, it should be removed quickly while the agarose gel was still hot. About 30 
min later the gel was cooled down and became solid. The comb was then removed 
and the gel was ready to use. 
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 Electrophoresis running 
  A gel electrophoresis apparatus (Bio-rad, Munich, Germany) was prepared. Gel 
made as described previously was put into the box filled with TBE buffer. PCR 
products (20 µl) were mixed with 3 µl DNA application buffer orange G sodium 
(Apotheke Klinikum Innenstadt, Munich, Germany). DNA ladder and PCR product 
mix were loaded into the slots made by the comb, each slot 5 µl. They were all loaded 
gently into the bottom of the slot first, then step back slowly to make sure all the 
sample was inside the slot. Then gel electrophoresis apparatus was connected to 
electric power. The negative terminal (black wire) was connected with the slots side 
and the positive terminal (red wire) was connected with the other side of the gel. 
Running was started at 80V for 15 min, then at 100V for about 30 min, which 
depended on actual situation.  
  The extent of running was judged by orange G sodium, which was orange color and 
can be seen in the gel. The perfect running time is to let the orange G sodium run to 
about 2/3 length of the gel. If running too long, the PCR products may run out of the 
gel, which may lead to the failure of the test. If running was too short, the DNA ladder 
may be not long enough to separate different molecular markers, which may cause 
difficulties in differentiation between target primer and the ladder. 
 
 Digital image taking 
  When gel electrophoresis was finished, digital images were made with Peqlab 
machine (Erlangen, Germany). As we can see in the following CD44 pair 1 gel 
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electrophoresis image Figure 1, compared with DNA ladder (the brightest stain was 
100 bp), stain of hMSCs were at the right place (CD44 pair 1 was 128 bp). Of all 4 
positive controls hMSC stains were positive. Annealing temperature 61℃ was 
brighter than the stain of 59 ℃ annealing temperature. Other primer pairs of CD44 
were not viable and showed no reasonable staining on the images. In summary, hMSC 
was chosen as positive control for viable primer CD44 pair 1 and the thermocycling 
protocol was also settled as tested.  
   Same procedures were applied for CD168, TLR4, CAP, CEMP1 and SCX (Table 
8). For SCX one primer pair was obtained from literature, another 3 primer pairs were 
self-designed as mentioned above. Finally the sequences obtained from literature were 
chosen. 
  Also for the housekeeping gene, glyceraldehyde-6-phosphate dehydrogenase 
(GAPDH), the primer was self-designed as done for the other genes (TIB-MOLBIOL, 
Berlin, Germany) and tested to make sure its practicable. Housekeeping gene means it 
is expressed in allmost every kind of cell type under any normal thermocycling 
condition. Therefore any cell type can be used as GAPDH positive control and in this 
study PDL cell’ cDNA was chosen and worked well. Also GAPDH is expressed 
under any normal thermocycling condition. In this study GAPDH was run under 3 
different thermocycling conditions and the primer was controlled if the thermocycling 
conditions are appropriate for it. 
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Figure	1	 	 CD44	pair	1	gel	electrophoresis	result-1. 
61℃	 	 45cycle 59℃	 	 45cycle  
PDL hMSC Bone 	 Teeth Neg. PDL	  hMSC Bone Teeth Neg. DNA	ladder 
 
 
 
Figure 1  CD44 pair 1 gel electrophoresis result. In DNA ladder the brightest stain was 
100bp. CD44 pair 1 was 128 bp. Stain of annealing temperature 61℃ was brighter than 59℃ 
in hMSC cDNA. Neg. was negative control. 
 
 
 
 
 
 
Table	9	 	 Primer	sequences,	positive	controls	and	thermocycling	conditions 
Primer	 Sequence 5’-3’	 Positive	control Annealing condition 	Length (bp)	
GAPDH	 for: CAA CTA CAT GGT TTA CAT GTT C rev: GCC AGT GGA 
CTC CAC GAC	 PDL 
61℃/65℃ x45cy 
or 
Touch down 
68-58℃x45cy	 181	
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Table	9	 	 Primer	sequences,	positive	controls	and	thermocycling	conditions 
CD44	 for: AGA AGA AAG CCA GTG CGT CTC rev: TGC TCT GCT GAG 
GCT GTA AAT 	 hMSC 61℃x45cy	 128	
CD168	 for: AGT CTT CGG AAT CAA AGG AAT CT rev: GCA TTT AGC CTT 
GCT TCC ATC   	 hMSC 61℃x45cy	 154	
TLR4	 for: CAG CTC TTG GTG GAA GTT GA 
rev: GCA AGA AGC 
ATC AGG TGA AA	 Colon	tissue 
Touch down 
68-58℃x45cy	 191	
CAP	 for: GGG GTC CAA GTG AGT TCA AGA   
rev: AAC CCA ACT CCT 
TTT TGT CCA  	 Caco-2 61℃x45cy	 183	
CEMP1	 for: TCA AGA CAA TCA CCC CTG AC   
rev: AAC CCT ATC TCT 
TCA CAC ATC C  	 Caco-2 65℃x45cy	 299	
SCX	 for: CCT GAA CAT CTG GGA AAT TTA ATT TTA C 
rev: CGC CAA GGC 
ACC TCC TT  	 tendon 
Touch down 
68-60℃x45cy	 111	
 
 
2.4.3 Osteogenic related primers 
  Osteogenic related primers were ALP, BSP, COL1A1 and OCN. They were 
provided directly by LightCycler primer set (Roche, Heidelberg, Germany). Primer 
set included primer, positive control, standard and standard stabilizer. Since they were 
provided by the company, viability test was done together with standard curve test 
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which will be introduced in detail in the following text. Thermocycling conditions of 
these primers are listed in Table 10. Primer sequence, product size, standard and 
positive control were trade secrets and were not provided by the company. GAPDH 
for OS markers was also obtained from LightCycler primer set (Roche, Heidelberg, 
Germany) and thermocycling condition was the same. 
 Table	10	 	 Thermocycling	conditions	of	osteogenic	related	primers. 
Primer	 Thermocycling condition	
ALP	
Touch down 68-60℃x45cy	
BSP	
Touch down 68-60℃x45cy	
COL1A1	
Touch down 68-60℃x45cy	
OCN	
Touch down 68-60℃x45cy	
 
 
 
 
 
 
 
2.4.4 rt-qPCR 
  All the samples (cDNA) were tested with quantitative real time polymerase chain 
reaction (rt-qPCR) machine LightCycler 480 (Roche, Mannheim, Germany). For 
nucleic acid stain, SYBR Green I Master (Roche, Mannheim, Germany) was used. 
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PCR grade H2O (Roche, Mannheim, Germany) was used during the entire process. 
  Firstly, a standard curve for each primer was made. Because self-designed primers  
and osteogenic related markers were obtained form different sources these two kinds 
of primers were operated differently in standard curve making.  
   cDNA samples were run with rt-qPCR and the CP values were detected. Gene 
expressions were counted according to their standard curve. Melting curves of each 
sample was checked, those values with wrong melting curve were deleted. Finally the 
relative expression was normalized against GAPDH as housekeeping gene. 
 
2.4.4.1  Standard curve of self-designed primer 
  For self-designed primers, only the primer was provided by the company. The 
positive control tested before was used as standard. PCR grade H2O (Roche, 
Mannheim, Germany) was used as  standard stabilizer.  
 
 Standard dilution 
  Firstly, 6 sterile 1.5 ml RNA-free eppendorf tubes (Merck, Munich, Germany) 
labeled with ‘STD 1:2’; ‘STD 1:4’; ‘STD 1:8’, STD 1:16’; ‘STD 1:32’; ‘STD 1:64’ 
were prepared. Then 30 µl CR grade H2O was pipetted into each tube. After that 30 µl 
cDNA of positive control of the primer was pipetted into the ‘STD 1:2’ tube, 
centrifuged and then mixed well. Then 30 µl ‘STD 1:2’ was pipetted into ‘STD 1:4’ 
tube, centrifuged and mixed as former step; other dilutions followed the same 
procedure. A separate tube of undiluted positive control cDNA was labeled with ‘STD 
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1:1’ and used for standard curve only. All the tips used for PCR were RNA-free and 
with filter. Tips were changed every time to avoid contamination. 
 
 rt-qPCR  
  A sterile 1.5 ml tube labeled as ‘PCR Master Mix’ was prepared. Appropriate 
amount of primer, H2O, and Syber Green I Master as presented in Table 11 were 
pipetted in and mixed well. Sample cDNAs were diluted into 1:20 (190 µl H2O and 10 
µl cDNA). 15 µl of the PCR Mix were pipetted into a 384-well PCR plate (Roche, 
Mannheim, Germany) and then 5 µl of diluted cDNA (1:20) were added as well. 
When pipetting was finished the plate was sealed with a special PCR parafilm (Roche, 
Mannheim, Germany). Then the plate was centrifuged 1500 rpm for 2 min to make 
sure all liquids were in the bottom of the wells and without bubbles. After that the 
plate was tested with rt-qPCR machine LightCycler 480 (Roche, Mannheim, 
Germany) with specific thermocycling conditions of different primers. 
 Table	11	 	 	 PCR	master	mix	preparation 
Primer  2.0 µl Master Mix for one sample: 
15.0 µl 
H2O      3.0 µl 
Syber Green I Master 10.0 µl 
Total Master Mix: 
Sample number x3 + positive control x3 + negative control x3 + STD dilution 
number x3 + 4 extra = PCR Mix 
 
	 46	
 
  Triplicate technical repeats were made for each sample. Each technical repeat 
represented by green points on the standard curve image (Figure 2). Those technical 
repeats (green points) with extreme deviation from the standard curve were deleted. 
Figure 2 was an example of self-designed primer: CD44’s standard curve. Other 
self-designed primers’ standard curves were alike. 
 
 
 
 
Figure 2  Standard curve of self-designed primer CD44. One colony of green points 
represent one standard dilution, from left to right ‘1:64; 1:32; 1:16; 1:8; 1:4; 1:2; 1:1’. 
 
 
2.4.4.2  Standard curve of osteogenic primer 
  The procedure of making standard curve for osteogenic primers was almost the 
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same as with self-designed primers, except for standard dilutions. For osteogenic 
primers, standard, standard stabilizer, positive control and primer were all provided by 
the LightCycler primer set (Roche, Heidelberg, Germany).  
  Firstly, 3 sterile 1 ml RNA-free eppendorf tubes (Merck, Munich, Germany) 
labeled with ‘STD 1:10’; ‘STD 1:100’; ‘STD 1:1000’ were prepared. Then 27 µl 
standard stabilizer was pipetted into each tube. After that 3 µl standard was pipetted 
into the ‘STD 1:10’ tube, centrifuged and then mixed well. Then 3 µl ‘STD 1:10’ was 
pipetted into ‘STD 1:100’ tube, centrifuged and mixed as former step, other dilutions 
followed the same procedure. Liquid was pipetted by the edge of the tube and tips 
were changed every time to avoid contamination. Then PCR master mix was made as 
in Table 11 and pipetted into a 384-well PCR plate (Roche, Mannheim, Germany) 
following the protocol as mentioned before. 
  Triplicate technical repeats were made for each dilution of osteogenic primers.  
Figure 3 presents an example of osteogenic primer showing the standard curve for 
ALP. Other osteogenic primers’ standard curves were alike. 
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Figure 3   Standard curve of self-designed primer CD44. One colony of green points 
represent one dilution of the standard, from left to right : '1:1000; 1:100; 1:10 and 
1:1’. Each dilution had 3 technique repeats.	
 
2.4.4.3 Technical repeats of PCR run 
  To prove the repeatability PCRs should be run at least twice and were run at 
different time. Therefore technical repeats of PCR run were required. Samples from 
the same cDNA dilution can share the same primer standard curve. Which means, 
when making PCR technical repeat, one standard dilution was required to be repeated 
together with the samples, as showed in Figure 4. Only standard part could be 
simplified, other procedures of PCR technical repeats were the same as for the first 
run. 
  In one PCR run each sample was made in triplicate technical repeats, and at least 
one PCR technical repeat (depend on the varieties of two data). The total technical 
repeats of one sample was at least six times.  
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Figure 4   PCR technique repeat standard curve. Two green points were repeated standard 
dilution 1:1. The  standard curve was made before.   
 
2.4.4.4 Melting curve control 
  The melting peaks of the same primer for all the samples in PCR should be the 
same. For those values who did not share the same melting peak with others, they 
were not  included into the final data analysis. Also, negative controls should not be 
in the same melting peak with the samples. As shown in Figure 5, most samples had 
the same melting temperature and formed the main peak; negative controls had either 
earlier melting peaks (two small peaks below 85 ℃) or no peaks (flat red lines 
beneath). 
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Figure 5  Melting curve of samples. Most of the samples had the same melting temperature 
(main peak); negative controls had either earlier melting peaks (two small peaks below 85 ℃) 
or no peaks (flat red lines beneath). For those values who did not share the same melting peak 
with others, they were not included in data analysis. 
 
 
2.4.4.5  CP value to gene expression  
 
  CP values were detected by PCRs. Sample concentrations were calculated 
according to the standard curve of different primers. Due to biodiversity, sample 
concentrations were controlled by housekeeping gene GAPDH. Controlled gene 
expression were then used for data analysis. The equation was as following: 
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Control equation 
Controlled primer expression = sample primer concentration / sample GAPDH 
concentration 
 
 
2.5 Von Kossa stain 
  Von Kossa stain is a quantified technique that can detect the mineral deposition of 
the cells. Cells were fixed, stained, dipicted photographically and compared by their 
shade. 
  hMSCs and PDLhTERTs were seeded in 12-well culture plates (Greiner bio-one, 
Frickenhausen, Germany) separately. Cells were divided into 8 groups, hMSC groups: 
control, +OS, +OS+nano HA and +OS+150k HA; PDLhTERT groups: control, +OS, 
+OS+nano HA and +OS+150k HA. All these groups were stimulated with different 
working medium as designed for 21 days and made von Kossa stain timely. For von 
Kossa stain, cells were firstly fixed, then stained.   
 
2.5.1 Cell fixing 
  At day 21, cells were harvested for von Kossa stain. Medium was aspirated from 
each well and cells were washed twice with PBS (Sigma Aldrich, Munich, Germany). 
Then each well was incubated with 1ml methanol (Carl Roth, Karlsruhe, Germany) 
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(20 min, -20℃). After that, the methanol was aspirated  from each well carefully 
(methanol discarded in a special bottle) and washed with distilled water.   
 
 2.5.2 Von Kossa stain     
  Fixed cells were firstly incubated with 5% Silver Nitrate (Merck KGaA, Darmstadt, 
Germany) in the dark (10 min, room temperature, Silver Nitrate discarded in a special 
bottle), and then washed with distilled water. After that cells were incubated with 1% 
Pyrogallol acid solution (University Pharmacy, Munich, Germany) 5 min for plasma 
dyeing and washed again with distilled water. Then cells were incubated with sodium 
hydroxide solution (Merck KGaA, Darmstadt, Germany) and rinsing carefully with 
tape water for 15 min. To get the nuclear stained, cells were incubated with 
May-Grünwald solution (Merck KGaA, Darmstadt, Germany) for 10 min and then 
washed with distilled water twice. Distilled water used for rising were all aspirated in 
former steps. After the last washing, 1 ml distilled water was kept in each well.  
 
Materials needed: 
 5% Silver Nitrate solution 15 ml     (M=169.87 g/mol)    
169.87 * 5% x 0.015L = 127.4025 mg diluted into 15ml distilled water 
 
 5% Sodium Nydroxide 15 ml     (45% NaOH in stock) 
5% * 15ml/ 45% = 1.67 ml diluted into 13.34ml H2O 
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2.5.3 Von Kossa stain images capture  
  After staining, images were captured by same person with the same digital camera 
(Nikon 7200, Natori, Japan) at the same place under the same light to minimize 
varieties. The photos were adjusted into black and white to refrain from chromatic 
aberration. 
 
2.6 Calcium deposition analysis 
  Calcium deposition analysis is a technique that can quantitatively detect calcium 
concentrations of cells. Cells were harvested and tested with enzyme-linked 
immunosorbent assay (ELISA). Calcium concentrations of samples were calculated 
according to the standard curve. 
  Cell culture and grouping for calcium deposition analysis were the same as used for 
von Kossa stain: hMSC groups: control, +OS, +OS+nano HA and +OS+150k HA; 
PDLhTERT groups: control, +OS, +OS+nano HA and +OS+150k HA. Cells were 
also stimulated for 21 days with designed working medium. 
  Cells were harvested with hydrochloric acid (Sigma, St. Louis, USA) and cell 
scrapers (Greiner bio-one, Frickenhausen, Germany). Culture medium was aspirated 
and each well was added into 500 µl hydrochloric acid. Then cells were scraped with 
cell scrapers and the turbid liquid was collected. Another 500 µl hydrochloric acid 
was added into each well to rinse cell fragments attached to the bottom and collected 
the liquid into the former tube of this well. Each well was checked under the 
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microscope to control whether all the cells were perfectly collected. Samples were 
stored in -20℃ fridge for future ELISA test. 
  QuantiChromTM Calcium Assay kit (Bioassay Systems, Basel, Switzerland) was 
used for the ELISA test to evaluate calcium concentration of samples. The kit 
contained standard, reagent A and reagent B. Standard dilutions were made as 
presented in Table 11. Total volume of each dilution was 100 µl. Standard 1 was the 
original standard and blank was H2O. Working reagent was reagent A combined with 
same volume of reagent B. Each well needed 200 µl working reagent. Samples were 
thawed in room temperature and mixed well. 5 µl of each sample was pipetted in a 
96-well flat bottom plate (Thermo Fisher, Waltham, USA) carefully. Then 200 µl 
regent was added into each well and incubated 3 min in room temperature. The results 
were all read with 612 nm wavelength in the same ELISA machine (TECAN, infinite 
M200, Switzerland) timely.  Duplicate technical sample repeats and triplicate ELISA 
run repeats were made like PCR test. 
 
OD value to calcium concentration 
  The following Table 12 was part of the raw data (OD value) of PDLhTERT 
calcium deposition ELISA. This is an example to explain how to calculate the calcium 
concentration from raw data.   
 Table	12	 	 Raw	data	of	PDLhTERT	calcium	deposition	ELISA. 
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Table	12	 	 Raw	data	of	PDLhTERT	calcium	deposition	ELISA. 
OD value of PDL-hTERT 1 Calcium deposition   (cell harvest on 22.06.16)	
 	 Run 1	 Run 2	 Run 3	
Blank	 0.6032	 0.6044	 0.5995	 0.5491	 0.546	 0.5481	 0.5377	 0.5404	 0.5343	
Standard1	 1.3536	 1.3516	 1.3549	 1.3274	  
Missing	 1.3769	 1.2884	 1.3039	 1.2393	
Standard2	 1.2011	 1.2197	 1.2188	 1.2439	 1.207	 1.2401	 1.182	 1.1941	 1.1806	
Standard3	 1.0851	 1.0586	 1.0544	 1.0611	 1.0824	 1.071	 1.0683	 1.0362	 1.0462	
Standard4	 0.9301	 0.9046	 0.9282	 0.9195	 0.9122	 0.9152	 0.8886	 0.8953	 0.8814	
Standard5	 0.8509	 0.8539	 0.8637	 0.8228	 0.8259	 0.8304	 0.815	 0.8139	 0.8079	
Standard6	 0.7577	 0.7683	 0.7786	 0.7398	 0.7382	 0.7407	 0.7225	 0.7281	 0.723	
Standard7	 0.6794	 0.6747	 0.6764	 0.6354	 0.6234	 0.6369	 0.6259	 0.6225	 0.6212	
PDL1 con1	 0.6407	 0.6455	 0.6505	 0.5951	 0.5899	 0.5919	 0.5734	 0.5716	 0.5715	
PDL1 con2	 0.626	 0.6388	 0.6359	 0.5838	 0.5839	 0.5781	 0.5636	 0.5632	 0.5612	
PDL1 con3	 0.6282	 0.6413	 0.6437	 0.5894	 0.5841	 0.5815	 0.5641	 0.5634	 0.5643	
PDL1 OS1	 0.7482	 0.7654	 0.769	 0.7462	 0.7274	 0.7375	 0.7154	 0.7081	 0.7065	
PDL1 OS2	 0.7623	 0.7632	 0.756	 0.7258	 0.7212	 0.7155	 0.6944	 0.7034	 0.704	
PDL1 OS2	 0.7274	 0.7164	 0.7276	 0.682	 0.6789	 0.6816	 0.6676	 0.6641	 0.6653	
PDL1 OS nano1	 0.7929	 0.7874	 0.7506	 0.7624	 0.7652	 0.7552	 0.7448	 0.7524	 0.7433	
PDL1 OS nano2	 0.7418	 0.7664	 0.7602	 0.735	 0.7293	 0.7307	 0.7069	 0.717	 0.7129	
PDL1 OS nano3	 0.7423	 0.7538	 0.756	 0.6025	 0.6088	 0.604	 0.5843	 0.5838	 0.5841	
PDL1 OS 150K1	 0.803	 0.8005	 0.8048	 0.7786	 0.7827	 0.7718	 0.7586	 0.7533	 0.7416	
PDL1 OS 150K2	 0.8068	 0.8036	 0.798	 0.6606	 0.6558	 0.6578	 0.635	 0.6388	 0.6458	
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Table	12	 	 Raw	data	of	PDLhTERT	calcium	deposition	ELISA. 
PLD1 OS 150K3	 0.7346	 0.7419	 0.7338	 0.5818	 0.5812	 0.5754	 0.5656	 0.5648	 0.5653	
 
 
 
 
 
 Table	13	 	 Calcium	deposition	standard	calculation	of	PDLhTERT. 
 
STD	+	H2O Standard concentration (mg/dl)	 OD Value (minus blank)	
Standard1	 100	µl	+	0	µl 20	 0.75103	
Standard2	 80	µl	+	20	µl 16	 0.61083	
Standard3	 60	µl	+	40	µl 12	 0.46363	
Standard4	 40	µl	+	60	µl 8	 0.3186	
Standard5	 30	µl	+	70	µl 6	 0.2538	
Standard6	 20	µl	+	80	µl 4	 0.16583	
Standard7	 10	µl	+	90	µl 2	 0.07446	
Blank	 0	µl	+	100	µl 0	 0	
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Figure 6  Standard of PDLhTERT Calcium deposition. Standard curve was made according 
to standards’ concentrations and OD values. Samples’ calcium concentrations were counted 
depend on the equation acquired from standard curve.   
 
 
  Standard curve was made according to the known concentration and OD value of 
the standards (Table 13). Equation was managed from the standard curve (Figure 6). 
For the standard in this run of PDLhTERT, the equation is:  
 
Y=0.0375x + 0.0112 
 
  R2 shows the accuracy of this equation. R2＞0.95 is suggested acceptable. So the 
concentration of the samples would be: 
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Concentration of sample = (OD of sample – OD of blank – 0.0112)/0.0375 
 
With this equation, all the samples were calculated for their calcium concentration. 
Samples’ calcium concentration were used for future data analysis. 
 
 
2.7 Statistical analysis 
  SPSS (version 22, SPSS Inc, Chicago, USA), Prism (version 7, Graph Pad 
Software, San Diego, USA) and Excel (version 14.1.0, Microsoft, Redmond, USA) 
used for data analysis. Standard deviation (SD) and standard error of mean (SEM) 
were used to describe the dispersion of the data. Tukey's multiple comparisons test 
was used to compare the difference between 2 groups. One-way Analysis of variance 
(ANOVA) was used to analysis among 3 or more group. P values <0.05 have been 
considered significant. 
  
 
3. Results 
3.1 Flow cytometry 
  The following figures (Figure 7-15) show the flow cytometry results of cells 
labeled with CD44, CD90 and CD168 markers.  
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3.1.1 CD44 
  Both CD44 and CD90 antibodies were with fluorescein. CD90 was used as a 
surrogate marker for hMSCs and PDLhTERTs. The mean fluorescence intensity 
(MFI) of CD44 and CD90 were presented as in Figure 7 and 10. Figure 8, 9, 11, 12 
showed the patten of cells labeled with CD44 and CD90 in flow cytometry. 
 
 
 
 
Figure 7  Mean fluorescence intensity (MFI) of PDLhTERTs labeled with CD44 and 
CD90 markers in flow cytometry. PDLhTERT groups: control, nano HA and 150k HA, 
stimulated for 7 days. 
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Figure 8    Histogram shows PDLhTRTs labeled with CD44 marker analyzed by flow 
cytometry. Black dotted line: unstained control; green line: 150k HA; red line: nano HA; grey 
line: control. 
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Figure 9    Histogram shows PDLhTRTs labeled with CD90 analyzed by flow cytometry. 
Black dotted line: unstained control; green line: 150k HA; red line: nano HA; grey line: 
control. 
 
 
 
Figure 10    Mean fluorescence intensity (MFI) of hMSCs labeled with CD44 and CD90 
markers in flow cytometry. hMSC groups: control, nano HA and 150k HA, stimulated for 7 
days. Dotted bar: control; lattice bar: 150k HA; stripes bar: nano HA. 
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Figure 11    Histogram shows hMSCs labeled with CD44 marker analyzed by flow 
cytometry. Black dotted line: unstained control; green line: 150k HA; red line: nano HA; grey 
line: control. 
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Figure 12    Histogram shows hMSCs labeled with CD90 marker analyzed by flow 
cytometry. Black dotted line: unstained control; green line: 150k HA; red line: nano HA; grey 
line: control. 
 
 
3.1.2 CD168 
 
  Because CD168 antibody was without fluorescein and incubated with secondary 
antibody, therefore the percent of positive cells was presented (Figure 13). 150k HA 
group of PDLhTERTs had the highest positive cells rate while control group of 
hMSCs was the highest. In Figure 14 and 15 show PDLhTERTs and hMSCs labeled 
with CD168 analyzed by flow cytometry. 
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Figure 13    Positive percent cells rate of PDLhTERTs and hMSCs labeled with CD168 
marker in flow cytometry. PDLhTERT groups: control, nano HA and 150k HA; hMSC 
groups: control, nano HA and 150k HA. Both cell types were stimulated for 7 days. Dotted 
bar: control; lattice bar: 150k HA; stripes bar: nano HA. 
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Figure 14   Histogram shows PDLhTRTs labeled with CD168 marker analyzed by flow 
cytometry. Black dotted line: unstained control; green line: 150k HA; red line: nano HA; grey 
line: control. 
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Figure 15   Histogram shows hMSCs labeled with CD168 marker analyzed by flow 
cytometry. Black dotted line: unstained control; green line: 150k HA; red line: nano HA; grey 
line: control. 
 
 
3.2 Immunofluorescence analysis 
 
  CD44 and CD168 antibodies were analyzed for both cell types. The following 
figures (Figure 16-19) show the results of immunofluorescence staining. 
 
3.2.1 CD44 
  CD44 is the main HA receptor. hMSCs labeled with CD44 showed prominently 
positive patten in the whole cytoplasm compared with unlabeled cells, as showed in 
Figure 16. For PDLhTERTs,  the staining was nearly negative in unlabeled groups. 
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The most prominent staining of PDLhTERT was in nano group (Figure 17). 
  
Figure 16   Immunofluorescence analysis of CD44 antibody in hMSC. A: control group 
labeled with CD44; B: nano HA group labeled with CD44; C: 150k HA group labeled with 
CD44; D: control without CD44; E: nano HA group without CD44; F: 150k HA group 
without CD44. 
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Figure 17   Immunofluorescence analysis of CD44 antibody in PDLhTERT. A: control 
group labeled with CD44; B: nano HA group labeled with CD44; C: 150k HA group labeled 
with CD44; D: control without CD44; E: nano HA group without CD44; F: 150k HA group 
without CD44. 
 
 
 
3.2.2 CD168 
  CD168 is also a very important HA receptor. hMSCs labeled with CD44 showed 
prominently positive patten in the whole cytoplasm compared with unlabeled cells 
(Figure 18). For PDLhTERTs, the staining was nearly negative in unlabeled groups. 
The most prominent staining of PDLhTERT was in nano group (Figure 19). 
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Figure 18   Immunofluorescence analysis of CD168 antibody in hMSC. A: control group 
labeled with CD44; B: nano HA group labeled with CD44; C: 150k HA group labeled with 
CD44; D: control without CD44; E: nano HA group without CD44; F: 150k HA group 
without CD44. 
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Figure 19   Immunofluorescence analysis of CD168 antibody in PDLhTERT. A: control 
group labeled with CD44; B: nano HA group labeled with CD44; C: 150k HA group labeled 
with CD44; D: control without CD44; E: nano HA group without CD44; F: 150k HA group 
without CD44. 
 	
3.3 Von Kossa stain 
  After 21 days，both cells formed tight membranes attached to the bottom of the 
wells. In von Kossa stain, different shade of color means different mineral deposition. 
As showed in Figure 20, there was barely any deposition of mineral aggregate in both 
control groups of two cell types. Therefore controls were more bright than other 
working groups. 
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   Among hMSC groups, +OS group showed deepest color followed by +OS+150k 
HA and +OS+nano HA group. As for PDLhTERTs groups, +OS+150k HA group 
seem to have the highest mineral aggregates, followed by +OS and +OS+nano HA 
groups. Von Kossa stain is an observational measurement of the mineral aggregates, 
quantitative measurement can be seen in the following calcium deposition analysis. 
 
 
 
 
Figure 20  Von Kossa stain for hMSCs and PDLhTERTs after 21 days of cell culture. The 
deeper the color, the more mineral aggregates deposition.  A: hMSC Control group; B: 
hMSC +OS group; C: hMSC +OS+nano HA HA group; D: hMSC +OS+150k HA group. E: 
PDLhTERT Control group; F: PDLhTERT +OS group; G: PDLhTERT +OS+ nano HA 
group; H: PDLhTERT +OS+150k HA group. Both control groups showed barely any mineral 
aggregates deposition. Among hMSCs groups: +OS ＞+OS+150kDa HA＞+OS+nano HA . 
PDLhTERTs groups: +OS+150kDa HA＞+OS＞ +OS+nano HA. 
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3.4 Calcium deposition analysis 
  Calcium deposition analysis is a quantitative measurement of calcium concentration 
of the cells. All the data were calculated as mentioned in materials and the final 
results of hMSCs are presented in Figure 21. For hMSC groups, the highest calcium 
concentration was obtained in the +OS group while the +OS+nano HA group was the 
lowest. Both +OS+nano HA and +OS+150kDa HA groups showed decreased 
expression of calcium compared with OS group (both P < 0.0001). +OS+nano HA 
expressed lower than +OS+150kDa HA groups (P < 0.0001).  All the groups had 
significantly higher calcium deposition than control group (P < 0.0001). 
  For PDLhTERT groups, as shown in Figure 22, the highest calcium expression 
seemed to be +OS+150kDa HA but there was no statistical significant difference 
when compared with OS group (p = 0.2426). However +OS+nano HA decreased the 
expression of calcium and was significant when compared to +OS group (p < 0.0001). 
+OS+150kDa HA also had higher expression than +OS+nano HA group (p < 0.0001). 
All the groups had significantly higher calcium deposition than control group 
( p<0.0001). 
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Figure 21  Calcium deposition results of hMSCs. Columns are representing the mean ± 
standard error (SD) of calcium deposits. The working groups had higher calcium expression 
than control groups (p<0.0001). Two groups with a comparison marker overhead had 
statistically significant difference (p<0.0001). 
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Figure 22  Calcium deposition results of PDLhTERTs. Columns are representing the mean ± 
standard error (SD) of calcium deposits. The working groups had higher calcium expression 
than control groups (p<0.0001). Two groups with a comparison marker overhead had 
statistically significant difference (p<0.0001). 
 
 
3.5 PCR results  
 3.5.1 CD44 
   In hMSCs the CD44 expression remained roughly unchanged during the entire 
observation period independent on the specific stimulation conditions, as in Figure 23. 
At day 21, the control group also expressed significantly less CD44 than +OS and 
+OS+150kDa HA groups (p=0.0002, p=0.0012), however no difference was found 
between +OS and HA groups. At day 3 and 21, the comparisons among all four 
groups were significant (p=0.0335; p<0.0001). 
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  Obviously PDLhTERTs’ CD44 expressions all peaked at day 7, as presented in 
Figure 24. CD44 expression was attenuated by stimulation. At day 3, +OS+nano and 
+OS+150k HA groups were significantly less expressed than +OS group (p=0.0117, 
p=0.0046). At day 7 nano HA was less expressed than +OS group (1p=0.0149); 
150kDa HA was also less than control, but no difference with +OS group. The 
comparisons among all four groups at day 3, 7 and 21 were all significant (p<0.0001; 
p=0.0009; p<0.0001). 
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Figure 23  Columns relative CD44 expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. In 
hMSCs the CD44 expression remained roughly unchanged during the entire observation 
period independent on the specific stimulation conditions.   
 
 
 
Figure 24  Columns relative CD44 expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. At day 3, +OS+nano and +OS+150k HA groups were significantly less expressed than 
OS group (p=0.0117, p=0.0046). At day 7 nano HA was less expressed than OS group 
(p=0.0149); 150kDa HA was also less than control, but no difference with OS group. 
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 3.5.2 CD168 
  CD168 expression trends of hMSCs and PDLhTERTs were similar. For both the 
+OS group was the highest at day 3, especially the +OS group of PDLhTERTs.  
  For hMSCs (Figure 25), CD168 expression was unaffected by stimulation. The 
comparisons among all four groups at day 7 and 21 were all significant (p=0.0251; 
p<0.0001). 
  For PDLhTERTs CD168 expression was inhibited by HA (Figure 26). At day 3, 
compared with +OS group, +OS+nano HA and +OS+150k HA depressed CD168 
expression (both p<0.0001), however no difference was found between +OS+nano 
HA and +OS+150k HA groups. The comparisons among all four groups at day 3 and 
7 were all significant (p<0.0001; p=0.0009). 
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Figure 25   Columns relative CD168 expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. 
hMSCs’ CD168 expression was almost unaffected by stimulation. 
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Figure 26   Columns relative CD168 expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. HA inhibited PDLhTERTs’ CD168 expression. Compared with +OS group, +OS+nano 
HA and +OS+150k HA depressed CD168 expression (both p<0.0001) at day 3. 
 
 
3.5.3 TLR4 
  hMSCs and PDLhTERTs showed almost the same trends of TLR4 expression. HA 
almost had no effect at first 3 time points and attenuated TLR4 expression at day 21.  
  For hMSCs (Figure 27), at day 21, +OS+nano HA group was significantly lower 
expressed than +OS group (p<0.0001). The comparisons among all four groups at day 
3, 7 and 21 were all significant (p=0.0003; p=0.0244; p<0.0001). 
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  In PDLhTERTs (Figure 28), HA seemed to have no effect during early stage 
stimulation, however attenuated TLR4 expression at day 21. At day 21, +OS+nano 
HA and +OS+150k HA group significantly attenuated TLR4 expression compared 
with +OS group (p<0.0001, p=0.0004). No significant difference was found between 
+OS+nano HA and +OS+150k HA group. The comparisons among all four groups at 
day 3, 7 and 21 were all significant (all p<0.0001). 
 
 
Figure 27    Columns relative TLR4 expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. At 
day 21, +OS+nano HA group was significantly lower expressed than +OS group (p<0.0001). 
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Figure 28    Columns relative TLR4 expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. In PDLhTERTs HA seemed to have no effect during early stage stimulation, however 
attenuated TLR4 expression at day 21. At day 21, +OS+nano HA and +OS+150k HA group 
significantly attenuated TLR4 expression compared with +OS group (p<0.0001, p=0.0004). 
 
 
 3.5.4 CAP 
  For hMSCs, (Figure 29) HA groups seemed to have no effect on CAP expression. 
At day 7, 150kDa HA had significantly higher expression than control (p<0.0001). At 
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day 21, all the working groups, +OS, +OS+nano HA and +OS+150k HA, expressed 
more CAP than control group (p<0.0001, p=0.0035, p=0.0004), however no 
significant difference among working groups. The comparisons among all four groups 
at day 3, 7 and 21 were all significant (p<0.0001, p=0.0002, p<0.0001). 
  For PDLhTERTs (Figure 30), CAP expression was inhibited by HA. At day 7, +OS 
and +OS+150k HA groups had higher expression than +OS+nano HA group 
(p=0.0002, p=0.0084), however no difference between +OS and +OS+150k HA 
groups. The comparisons among all four groups at day 3, 7 and 21 were all significant 
(p<0.0001, p= 0.014, p<0.0001). 
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Figure 29  Columns relative CAP expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. For 
hMSCs, stimulation seemed to have no effect on CAP expression. 
 
 
 
Figure 30   Columns relative CAP expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. At day 7, +OS and +OS+150k HA groups had higher expression than +OS+nano HA 
group (p=0.0002, p=0.0084). 
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 3.5.5 CEMP1 
  Both nano and 150kDa HA inhibited hMSCs’ CEMP1 expression (Figure 31). At 
day 7 CEMP1 expressions of +OS and +OS+150k HA groups were prominently 
higher than +OS+nano HA group (p<0.0001, p=0.0069). At day 21, +OS group  
expression was prominently higher than +OS+nano HA and +OS+150k HA group 
(p<0.0001, p=0.0046), however no difference was found between +OS+150k HA and 
+OS+nano HA groups. The comparisons among all four groups at day 7 and 21 were 
significant (both p<0.0001). 
  For PDLhTERTs the peak of CEMP1 expression was at day 7 (Figure 32).  At day 
7, +OS group was significantly higher than +OS+nano HA and +OS+150k HA groups 
(p<0.0001, p=0.0181), however no difference was found between nano and 150kDa 
HA. The comparisons among all four groups at day 3, 7 and 21 were all significant 
(p=0.0002, p=0.0003, p<0.0001). 
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Figure 31   Columns relative CEMP1 expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. 
Both nano and 150kDa HA inhibited hMSCs’ CEMP1 expression. At day 7 CEMP1 
expressions of +OS and +OS+150k HA groups were prominently higher than +OS+nano HA 
group (p<0.0001, p=0.0069). At day 21, +OS group CEMP1 expression was prominently 
higher than +OS+nano HA and +OS+150k HA group (p<0.0001, p=0.0046). 
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Figure 32   Columns relative CEMP1 expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. At day 7, +OS group was significantly higher than +OS+nano HA and +OS+150k HA 
groups (p<0.0001, p=0.0181). 
 
 
 3.5.6 SCX 
  Both hMSCs and PDLhTERTs had very low expression of SCX. In the current 
study the expression of SCX remained almost unchanged irrespective of the specific 
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stimulation condition for both cells. 
  For hMSCs (Figure 33), stimulation almost had no effect on its SCX expression. At 
d ay 3 control was also significantly higher than +OS+nano HA group (p= 0.0229). At 
day 21, +OS group expressed higher SCX than control group (p=0.0445). No 
significant difference was found among working groups. The comparisons among all 
four groups at day 3 and 21 were significant (p=0.0087, p<0.0001). 
 PDLhTERTs expressed more SCX than hMSCs (Figure 34). However no difference 
was found between any groups during all 21 days of culture. Only the comparisons 
among all four groups on 21 was significant (p=0.0021). 
 
 
Figure 33   Columns relative SCX expression [mean ± standard error of mean (SEM)] of 
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hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene.  
HA stimulation almost had no effect on hMSCs’ SCX expression.  
 
 
 
Figure 34   Columns relative SCX expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. PDLhTERTs expressed SCX, however no difference was found between any groups 
during all 21 days of culture. 
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 3.5.7 ALP 
   hMSCs and PDLhTERTs showed completely opposite trends of ALP expression. 
  For hMSCs (Figure 35), at day 3 and 7 +OS+nano HA expressed more ALP than 
the +OS group of the same time points (p=0.0348, p=0.0254). At day 21, both 
+OS+nano HA and +OS+150k HA had higher expression than +OS group (p=0.0332, 
p<0.0001); +OS+150k HA was also statistically higher than +OS+nano HA 
(p=0.0063). Control groups of each time points were significantly lower expressed 
than working groups. The comparisons among all four groups at day 3, 7 and 21 were 
all significant (all p< 0.0001). 
 PDLhTERTs had very low and flat ALP expression on first 3 time points, but 
increased markedly at day 21, especially +OS+nano HA and +OS+150k HA groups 
(Figure 36). At day 21, both +OS+nano HA and +OS+150k HA expressed more ALP 
than +OS group (both p<0.0001), but no significant expression between +OS+nano 
HA and +OS+150k HA. The comparisons among all four groups at day 3, 7 and 21 
were all significant (p=0.0299, p<0.0001, p< 0.0001). 
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Figure 35   Columns relative ALP expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. At 
day 3 and 7 hMSCs +OS+nano HA expressed more ALP than the +OS group of the same 
time points (p=0.0348, p=0.0254). At day 21, both +OS+nano HA and +OS+150k HA had 
higher expression than +OS group (p=0.0332, p<0.0001); +OS+150k HA was also 
statistically higher than +OS+nano HA (p=0.0063). 
 
	 91	
 
 
Figure 36   Columns relative ALP expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. At day 21, both +OS+nano HA and +OS+150k HA expressed more ALP than +OS 
group (both p<0.0001). 
 
 
 3.5.8 BSP 
  HA seemed to have no effect on hMSCs’ BSP expression (Figure 37). At day 7, 
hMSCs’ +OS+150k group expressed more BSP than +OS+nano HA (p<0.0001), 
however no difference was found between +OS+150k HA and +OS groups. There 
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was no significant difference of BSP expression among groups,  the only exception 
was day 7 (p=0.0039). 
 For PDLhTERTs (Figure 38), stimulation also had no effect on BSP expression. 
There was no significant difference of BSP expression among groups from day 0 to 
day 7,  the only exception was day 21 (p=0.0002). 
 
 
 
Figure 37  Columns relative BSP expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. HA 
seemed to have no effect on hMSCs’ BSP expression. At day 7, +OS+150k HA expressed 
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more BSP than +OS+nano HA (p<0.0001). 
 
 
 
 
Figure 38   Columns relative BSP expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. Standard deviation was used for all data. HA seemed to have no effect on PDLhTERTs’ 
BSP expression. 
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 3.5.9 COL1A1 
  hMSCs and PDLhTERTs showed opposite COL1A1 expression trends during 21 
days of cell culture.  
  For hMSCs (Figure 39), +OS+nano group had higher COL1A1 expression than 
+OS group at day 3 (p=0.001). The comparisons among all four groups at day 3 and 7 
were significant (p=0.0095, p<0.0001). 
  For PDLhTERTs (Figure 40), at day 21, +OS+150k HA group expressed the 
highest amount of COL1A1. +OS+150k HA had significantly higher COL1A1 
expression than +OS+nano and +OS group (np=0.0111, p<0.0001). +OS+nano HA 
was also higher than +OS group (p=0.0056). The comparisons among all four groups 
at day 3, 7 and 21 were all significant (p=0.0007, p<0.0001, p=0.0016). 
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Figure 39    Columns relative COL1A1 expression [mean ± standard error of mean (SEM)] 
of hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 
21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. 
+OS+nano group had higher COL1A1 expression than +OS group at day 3 (p=0.001). 
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Figure 40    Columns relative COL1A1 expression [mean ± standard error of mean (SEM)] 
of PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. At day 21, +OS+150k HA group expressed the highest amount of COL1A1. +OS+150k 
HA had significantly higher COL1A1 expression than +OS+nano and +OS group (p=0.0111, 
p<0.0001). +OS+nano HA was also higher than +OS group (p=0.0056). 
 
 
 3.5.10 OCN 
   On both, day 3 and 7, +OS+nano HA group of hMSC expressed higher OCN than 
+OS group (p=0.002, p=0.0031), as showed in Figure 41. However +OS+150k HA 
had no significant difference when compared with +OS group. The comparisons 
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among all four groups at day 3, 7 and 21 were all significant (p=0.0051, p=0.0088, 
p<0.0001). 
  The OCN expression of PDLhTERTs was attenuated by 150kDa HA stimulation 
(Figure 42). At day 7, +OS group was higher expressed than +OS+150k HA group 
(p=0.026). The comparisons among all four groups at day 7 and 21 were significant 
(p<0.0001, p=0.0009). 
 
 
 
Figure 41   Columns relative OCN expression [mean ± standard error of mean (SEM)] of 
hMSCs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 and 21 
days. Relative CD 44 expression was normalized against GAPDH as housekeeping gene. On 
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both day 3 and 7, +OS+nano HA expressed higher OCN than +OS group (p=0.002, 
p=0.0031). 
 
 
 
 
 
 
Figure 42   Columns relative OCN expression [mean ± standard error of mean (SEM)] of 
PDLhTERTs for control, +OS, +OS+nano and +OS+150k groups which cultured for 0, 3, 7 
and 21 days. Relative CD 44 expression was normalized against GAPDH as housekeeping 
gene. At day 7, +OS group was higher expressed than +OS+150k HA group (p=0.026). 
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4. Discussion 
  This study aimed to delineate the effects of low molecular weight fragments of HA 
on the cementogenic, ligamentogenic and osteogenic differentiation of PDLhTERTs 
and hMSCs. Both types of cells can be found within periodontal tissues and were, 
accordingly, suggested to play a central role in the regeneration of periodontal defects 
(Silverio et al. 2008, Suaid et al. 2011, Sanchez-Lara 2013). For periodontal tissue 
regeneration, stem cells have to differentiate into osteoblasts, periodontal ligament 
cells, and cementoblasts (Maeda et al. 2011). Comparable as in wounds also in 
pathogenic tissue defects native high molecular weight HA is fragmented during 
tissue repair (McAtee et al. 2014, Parsons 2015). In comparison to native HA the low 
molecular fragments have the potential to interact with stem cells and to promote their 
in-trafficking into the healing tissue defect (Kota et al. 2014, Veiseh et al. 2015).  
 
4.1 HA markers 
  Among other marker molecules, which are characteristic for mesenchymal stem 
cells, specifically the CD44 receptor is highly expressed in these cells (Choi et al. 
2015). CD44 is the main cell surface receptor interacting with HA (Aruffo et al. 1990) 
which, upon binding to HA, regulates various biological functions including 
proliferation and differentiation (Viola et al. 2015). CD168/CD138 represents the 
second major receptor for HA (Cheung et al. 1999). Due to alternative splicing also 
this receptor is expressed in various isoforms depending on the specific cell type 
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(Kavasi et al. 2017). Unlike the CD44 receptor the CD168 receptor is only sparsely 
expressed on the cell surface (Nikitovic et al. 2016). In-vitro experiments on human 
keratinocytes revealed that HA enhances the expression of both, the CD44 and the 
HMMR gene showing a strong positive correlation with the molecular weight of HA 
(D'Agostino et al. 2017). In fibrocytes HMW-HA increased the expression of CD44 
receptors but opposed to that LMW-HA caused a significant inhibition (Maharjan et 
al. 2011). Herein, both receptor genes have been substantially expressed in both cell 
types. In hMSCs the expression, however, remained roughly unchanged during the 
entire observation period independent on the specific stimulation conditions. On the 
contrary in PDLhTERTs the presence of small oligosaccharides nano and/or the 
150kDa HA fragment significantly attenuated the expression of the CD44 receptor, 
however no difference was found between nano and 150kDa HA. A recent study has 
reported that the proliferation and mineralization capacities of PDL cells are 
inevitably bound to the presence of the CD44 receptor (Yeh et al. 2014). Based on 
these results it can be assumed that the differentiation of PDLhTERTs is more 
advanced than that of hMSCs consequently being more susceptible to stimuli 
modifying the expression of CD44. Despite being classified as pluripotent stem cells, 
both types of cells have a different ontogenetic nature (Proksch et al. 2012, Proksch et 
al. 2014). Whereas hMSCs can be considered as true mesenchymal cells, 
PDLhTERTs are derived from the neural crest and are therefore assigned to have an 
ectomesenchymal origin. Hence, in comparison to hMSCs the PDLhTERTs might 
have a less undifferentiated phenotype reacting more instantly on extrinsic stimuli 
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inducing cell differentiation.  
  Consistent results have been obtained for the expression of the CD168 receptor, 
which has been almost unaffected in hMSCs but was inhibited by HA in 
PDLhTERTs. OS medium enhanced PDLhTERTs’ CD168 expression. Both nano and 
150kDa HA inhibited CD168 expressions, however no significant difference was 
found between these two different molecular weight HA. Recent observations on 
mesenchymal progenitor cells revealed that the expression of the CD44 and the 
CD168 receptor are closely interrelated (Veiseh et al. 2015). Specifically the CD168 
receptor seems to control the CD44 expression along with the perception of HA. 
Hence, linkage between the expression of CD44 and the CD168 receptor might 
explain the comparable changes under HA stimulation in PDLhTERTs.  
  TLRs were reported to be able to activate keratinocytes’ reaction toward injury 
without CD44, the main receptor (Gariboldi et al. 2008). The up regulation of TLR4 
may activate NF-κB in the mouse MSCs, which will increase prostaglandin E2 
(PGE2) secretion and finally enhance inflammation (Prockop et al. 2012). A former 
study indicated that TLR4 expression of hMSCs were almost the same after 1 and 7 
days of osteogenic stimulation, but decreased slightly after 14 days (Ebert et al. 2015). 
In this study TLR4 expressions of both hMSCs and PDLhTERTs were attenuated by 
nano and/or 150k HA. OS  medium enhanced TLR4 expression for both cells. TLR4 
blocking was also reported to inhibit osteogenetic differentiation of MSCs when 
cultured with OS medium (Herzmann et al. 2017).  
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4.2 Cementogenic differentiation 
  For the initiation of periodontal regeneration including the re-formation of fibrous 
attachment the development of new cementum on the root surface comprises the 
central step (Saygin et al. 2000). Yet, two marker molecules, i.e. CAP and CEMP1 
have been identified to be specifically expressed in cementogenic cells (Liu et al. 
1997, Alvarez-Perez et al. 2006). Osteogenic stimulation was reported to inhibit CAP 
and CEMP1 expression of PDL stem cells at day 15. Extra supplement of vitamin C 
(VC) can reverse inhibition and enhance cementogenic differentiation (Gauthier et al. 
2017). 
   In this study, HA inhibited cementogenic differentiation of both cell types. HA 
had no effect on hMSCs’ CAP expression; while nano HA obviously inhibited 
PDLhTERTs’ CAP expression. Nano and 150kDa HA attenuated CEMP1 expression 
of both hMSCs and PDLhTERTs. PDLhTERTs showed the highest expression of 
both cementogenic marker molecules already after day 7 whereas in hMSCs an 
increasing expression was found until day 21. This observation, again, can be 
explained by biological differences between both types of stem cells leading to a 
varying responsiveness to extrinsic growth stimuli (Luan et al. 2009). Despite these 
potential phenotypic differences the presence of HA reduced the transcription of the 
cementogenic marker molecules in both cell types. 
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 4.3 Ligamentogenic differentiation 
  Scleraxis is a transcription factor that can be found in progenitor cells of tendon and 
in PDL cells. Typically it is used as marker molecule indicating differentiation of 
stem cells towards periodontal ligament fibroblasts, i.e. (Seo et al. 2004, Inoue et al. 
2012). In the current study the expression of this marker remained almost unchanged 
irrespective of the specific stimulation condition for both hMSCs and PDLhTERTs. 
 
 
 4.4 Osteogenic differentiation 
  OS medium can enhance ALP, BSP, COL1A1 and OCN expressions in hMSCs 
(Sila-Asna et al. 2007). All the experimental groups were with OS medium in this 
study. Regarding the osteogenic differentiation the expression of ALP was induced by 
the various stimulation conditions in both, hMSCs and PDLhTERTs. Intriguingly, it 
was considerably stronger in the presence of oligosaccharide nano and 150 kDa HA. 
HA accelerated hMSCs’ ALP expression obviously, 150kDa HA was even stronger 
than nano HA. In contrast to the cementogenic marker molecules the expression of 
ALP was significantly stronger in hMSCs already at shorter periods of time as 
compared to PDLhTERTs. PDLhTERTs’ ALP expression was increased markedly by 
HA at day 21, however no difference was found between nano and 150kDa HA.The 
specific origin of hMSCs from the bone marrow might provide a plausible 
explanation for their prompter osteogenic differentiation. ALP is considered as marker 
molecule indicating the early mineralization process by hydrolyzing phosphate esters 
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subsequently accumulating phosphate ions within the ECM (Malaval et al. 1999, 
Viereck et al. 2002).  
  BSP contributes to bone, cementum and dentin mineralization and has angiogenic 
capacity (Ogata 2008, Bouleftour et al. 2016). BSP can be used in collagen scaffold 
coating to increase bone tissue repair ( Kruger et al. 2013). Therefore BSP expression 
can be very important for periodontal regeneration. However in this study HA seemed 
to have no effect on both cells’ BSP expression.  
 Except for BSP also the expression of the osteogenic marker molecules representing 
later stages of osteogenic differentiation, i.e. COL1A1 and OCN seemed to be 
enhanced by the HA fragments.  
   Type I collagen is an essential component of the dermis, bone, and tendon matrix. 
COL1A1 was also considered as an early marker of osteogenic differentiation 
(Weinreb et al. 1990). HMW-HA was reported to express less COLL1A1 than 
LMW-HA and high-low molecular HA mix complex at day 2 (D'Agostino et al. 
2015). In this study, nano HA seemed to be able to increase hMSCs’ COL1A1 
expression at day 3. For PDLhTERTs, COL1A1 expression was increased by both 
nano and 150kDa HA at day 21, especially 150kDa HA. A study of hBMSCs cultured 
with HA hydrogels showed increased COL1A1 and OCN expressions with longer 
time of stimulation and higher HA concentration in the hydrogels (Jung et al. 2018). 
Administration route, HA molecule weight and HA concentration may effect HA’s 
function on cells.  
  OCN was the only late osteogenic differentiation marker of the four chosen 
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markers in this work and has been described to be essential for bone formation (Ducy 
et al. 1996). In this study the OCN expression of hMSCs was increased by nano HA, 
however 150kDa HA seemed to have no effect on it. For PDLhTERTs, 150kDa HA 
slightly attenuated  OCN expression. 
   In general, HA roughly increased ALP, COL1A1 and OCN expressions of hMSCs 
and PDLhTERTs. For OCN, nano HA increased its expression in hMSCs but 150kDa 
HA decreased it in PDLhTERTs. Nano HA seemed always to be an accelerator while 
150kDa HA sometimes was an inhibitor. As we know hMSCs have more osteogenic 
differentiation potential than PDLhTERTs (Docheva et al. 2010, Egusa et al. 2012). 
The difference of HA effected osteogenic markers expressions may be because 
hMSCs were earlier differentiated (in first 7 days) than PDLhTERTs (started from 
day 21). Stem cell differentiation direction and degree were effected by many factors 
in the environment, such as cell morphology, cell density, virus infection, stimulant, 
and differentiation media. Cell density will effect cell shape and influence 
differentiation directly (McBeath et al. 2004). In this study cells were seeded in the 
same density and without virus infection. However hMSCs and PDLhTERTs growth 
velocity were different, which may lead to different densities at later stimulation. This 
may also explain the difference of expressions between hMSC and PDLhTERT. 
  Calcium deposition is commonly suggested as end-stage osteogenic marker. 
Regarding this marker both, the osteogenic stimulation alone and together with HA 
lead to the highest calcium deposition. In both cell types there was, however, a trend 
for an inhibitory effect on calcium deposition for HA which seemed to be stronger for 
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the nano HA as compared to the 150 kDa HA. Partially in line with the current results, 
in osteoblastic cells of rodents the 60 kDa HA did not cause changes in ALP activity 
but induced a significant stronger transcription of osteocalcin as compared to 
unstimulated controls (Huang et al. 2003). In addition, the HA with the lower 
molecular mass of 60 kDa did not enhance the mineralization as compared to the high 
molecular mass HA of 900 kDa and 2300 kDa respectively. Contradictory to the 
present results another study using porcine bone marrow derived mesenchymal cells 
observed a strong reduction of the expression of osteogenic differentiation markers, 
i.e. COLIA1 and ALP, in the presence of HA. However, in this study the HA used for 
stimulation and leading to a significant enhancement of calcium deposition after 21 
days had a considerably higher molecular mass of 900 kDa (Zou et al. 2008).   
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5. Conclusion 
  Periodontitis is a highly prevalent chronic inflammatory oral disease which leads to 
bone loss, attachment loss and, ultimately, to tooth loss. HA is a non-sulfated 
glycosaminoglycan that can be found extensively in human tissue including 
periodontal tissue. HA was reported to have significant influence on periodontal tissue 
repair and has already been widely used in medical applications. This study aimed to 
delineate the effects of various sized HA molecules on periodontal cells hMSCs and 
PDL-hTERTs. The HA receptors CD44, CD168 and the TLR4 have been 
substantially expressed in both cell types. In hMSCs CD44 and CD168 expression 
remained roughly unchanged during the entire observation period; in PDLhTERTs 
small nano and/or the 150 kDa HA fragment significantly attenuated the expression of 
the CD44 receptor. TLR4 expression was inhibited by nano and/or 150kDa HA in 
both cell types at day 21. In addition, the presence of HA reduced the transcription of 
the cementogenic marker molecules in both cell types, especially nano HA. SCX, a 
ligamentogenic marker, remained almost unchanged irrespective of the specific 
stimulation condition. Early stage osteogenic marker ALP was induced by the various 
stimulation conditions in both hMSCs and PDLhTERTs and stronger in the presence 
of nano and 150 kDa HA. BSP remained roughly unchanged under stimulation. 
Osteogenic markers COL1A1 in both cell types and OCN in hMSCs were also 
enhanced by the HA fragments. However OCN expression in PDLhTERTs it was 
inhibited by 150k HA. The osteogenic stimulation alone and together with HA lead to 
the highest calcium deposition.  
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  Taken together the current study revealed that small HA fragments cause 
differential effects on hMSCs and PDLhTERTs. Nano HA seemed to have more 
positive effects in osteogenic differentiation than 150kDa HA. These fragments seem 
to enhance the earlier steps of osteogenic differentiation in both types of cells but to 
impair the expression of cementogenic differentiation markers and the mineralization 
of the ECM during osteogenesis within 21 days. Since the expression of SCX was 
unaffected HA seems to have no influence on the ligamentogenesis.  
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6. Supplementary data  
  Here were rt-qPCR results of 10 primers, Table 14 included HA receptors CD44, 
CD168 and TLR4; Table 15 included OS markers ALP, BSP, COL1A1 and OCN; 
Table 16 included cementogenic and ligamentogenic markers CAP, CEMP1 and 
SCX. Comparison between two samples was used Tukey's multiple comparisons test. 
Comparison of four groups at the same time point was used One-way ANOVA, 
presented in Table 17. PDLhTERT was simply written as ‘PDL’ in all following 
tables. 
 Table	14	 	 PCR	positive	results	of	HA	receptors 
Tukey's multiple comparisons test	 Mean 
Diff.	
95.00% CI of 
diff.	
Summ
ary	
Adjusted P 
Value	
CD44	 hMSC-7d-con vs. 
hMSC-21d-con	
0.3189	 0.0386 to 
0.5992	
*	 0.0113	
hMSC-21d-con vs. 
hMSC-21d-OS	 -0.4449	 -0.752 to -0.1379	 ***	 0.0002	
hMSC-21d-con vs. 
hMSC-21d-OS150k	 -0.4043	 -0.7113 to -0.09726	 **	 0.0012	
PDL-3d-con vs. PDL-3d-OS	 0.6173	 0.02333 to 
1.211	 *	 0.0335	
PDL-3d-con vs. 
PDL-3d-OSnano	 1.282	 0.6876 to 1.876	 ****	 <0.0001	
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Table	14	 	 PCR	positive	results	of	HA	receptors 
PDL-3d-con vs. 
PDL-3d-OS150k	 1.327	 0.7328 to 1.921	 ****	 <0.0001	
PDL-3d-con vs. PDL-7d-con	 -0.7148	 -1.309 to 
-0.1209	 **	 0.0051	
PDL-3d-con vs. PDL-21d-con	 0.7425	 0.06286 to 
1.422	 *	 0.0189	
PDL-3d-OS vs. PDL-3d-OSnano	 0.6642	 0.07878 to 
1.25	 *	 0.0117	
PDL-3d-OS vs. PDL-3d-OS150k	 0.7095	 0.1241 to 
1.295	 **	 0.0046	
PDL-3d-OS vs. PDL-7d-OS	 -0.9605	 -1.546 to 
-0.3751	 ****	 <0.0001	
PDL-3d-OS vs. PDL-21d-OS	 0.8631	 0.2086 to 
1.518	 **	 0.0011	
PDL-3d-OSnano vs. 
PDL-7d-OSnano	 -0.9728	 -1.558 to -0.3874	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-7d-OS150k	 -1.602	 -2.187 to -1.016	 ****	 <0.0001	
PDL-7d-con vs. 
PDL-7d-OSnano	 1.024	 0.4381 to 1.609	 ****	 <0.0001	
PDL-7d-con vs. PDL-21d-con	 1.457	 0.7852 to 
2.129	 ****	 <0.0001	
PDL-7d-OS vs. PDL-7d-OSnano	 0.6519	 0.06648 to 
1.237	 *	 0.0149	
PDL-7d-OS vs. PDL-21d-OS	 1.824	 1.169 to 2.478	 ****	 <0.0001	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 1.19	 0.5354 to 1.844	 ****	 <0.0001	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 1.806	 1.151 to 2.46	 ****	 <0.0001	
PDL-21d-con vs. PDL-21d-OS	 0.738	 0.004854 to 
1.471	 *	 0.0468	
PDL-21d-con vs. 
PDL-21d-OSnano	 0.7562	 0.02305 to 1.489	 *	 0.0363	
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Table	14	 	 PCR	positive	results	of	HA	receptors 
PDL-21d-con vs. 
PDL-21d-OS150k	 0.7887	 0.05554 to 1.522	 *	 0.0227	
CD16
8	 hMSC-3d-con vs. hMSC-7d-con	 1.96	 0.5664 to 3.354	 ***	 0.0003	
hMSC-3d-con vs. 
hMSC-21d-con	 3.713	 2.154 to 5.271	 ****	 <0.0001	
hMSC-3d-OS vs. hMSC-7d-OS	 1.593	 0.1989 to 
2.987	 *	 0.0106	
hMSC-3d-OS vs. hMSC-21d-OS	 4.043	 2.485 to 5.601	 ****	 <0.0001	
hMSC-3d-OSnano vs. 
hMSC-21d-OSnano	 2.838	 1.28 to 4.396	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-21d-OS150k	 2.592	 1.034 to 4.151	 ****	 <0.0001	
hMSC-7d-con vs. 
hMSC-21d-con	 1.752	 0.194 to 3.311	 *	 0.0131	
hMSC-7d-OS vs. hMSC-21d-OS	 2.45	 0.892 to 4.009	 ****	 <0.0001	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 2.235	 0.677 to 3.794	 ***	 0.0002	
hMSC-7d-OS150k vs. 
hMSC-21d-OS150k	 2.525	 0.9671 to 4.084	 ****	 <0.0001	
PDL-3d-con vs. PDL-3d-OS	 -66.68	 -74.97 to 
-58.38	 ****	 <0.0001	
PDL-3d-con vs. 
PDL-3d-OSnano	 -10.73	 -18.9 to -2.556	 **	 0.0012	
PDL-3d-con vs. 
PDL-3d-OS150k	 -9.807	 -17.98 to -1.633	 **	 0.0053	
PDL-3d-con vs. PDL-21d-con	 9.925	 0.7867 to 
19.06	 *	 0.0202	
PDL-3d-OS vs. PDL-3d-OSnano	 55.95	 47.65 to 64.24	 ****	 <0.0001	
PDL-3d-OS vs. PDL-3d-OS150k	 56.87	 48.58 to 65.16	 ****	 <0.0001	
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Table	14	 	 PCR	positive	results	of	HA	receptors 
PDL-3d-OS vs. PDL-7d-OS	 76.12	 67.71 to 84.53	 ****	 <0.0001	
PDL-3d-OS vs. PDL-21d-OS	 75.84	 66.59 to 85.08	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-7d-OSnano	 15.72	 7.546 to 23.89	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-21d-OSnano	 20.53	 11.39 to 29.67	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-7d-OS150k	 14.68	 6.508 to 22.86	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-21d-OS150k	 19.43	 10.29 to 28.57	 ****	 <0.0001	
TLR4	 hMSC-3d-OS vs. hMSC-21d-OS	 -208.5	 -262.3 to 
-154.8	 ****	 <0.0001	
hMSC-3d-OSnano vs. 
hMSC-21d-OSnano	 -125.7	 -177.9 to -73.52	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-21d-OS150k	 -173.4	 -224.2 to -122.5	 ****	 <0.0001	
hMSC-7d-OS vs. hMSC-21d-OS	 -223.1	 -275.2 to 
-170.9	 ****	 <0.0001	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 -143.8	 -193.6 to -94.1	 ****	 <0.0001	
hMSC-7d-OS150k vs. 
hMSC-21d-OS150k	 -176	 -229.7 to -122.2	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OS	 -220.1	 -269.9 to -170.4	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OSnano	 -141.1	 -190.8 to -91.34	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OS150k	 -175.4	 -225.1 to -125.6	 ****	 <0.0001	
hMSC-21d-OS vs. 
hMSC-21d-OSnano	 79.04	 29.29 to 128.8	 ****	 <0.0001	
PDL-3d-OS vs. PDL-21d-OS	 -43.91	 -52.72 to 
-35.09	 ****	 <0.0001	
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Table	14	 	 PCR	positive	results	of	HA	receptors 
PDL-3d-OSnano vs. 
PDL-21d-OSnano	 -27.53	 -37.19 to -17.87	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-21d-OS150k	 -30.78	 -40.21 to -21.34	 ****	 <0.0001	
PDL-7d-OS vs. PDL-21d-OS	 -41.65	 -50.46 to 
-32.83	 ****	 <0.0001	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 -25.26	 -34.92 to -15.6	 ****	 <0.0001	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 -29.57	 -38.58 to -20.55	 ****	 <0.0001	
PDL-21d-con vs. PDL-21d-OS	 -37.68	 -46.49 to 
-28.86	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OSnano	 -22.03	 -31.28 to -12.79	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OS150k	 -24.95	 -33.96 to -15.93	 ****	 <0.0001	
PDL-21d-OS vs. 
PDL-21d-OSnano	 15.64	 6.396 to 24.89	 ****	 <0.0001	
PDL-21d-OS vs. 
PDL-21d-OS150k	 12.73	 3.715 to 21.74	 ***	 0.0004	
  
 
 
 
 
 
 Table	15	 	 	 PCR	positive	results	of	OS	markers 
Tukey's multiple comparisons test	 Mean 
Diff.	 95.00% CI of diff.	 Significance	 P Value	
ALP	 hMSC-3d-con vs. 
hMSC-3d-OS	 -0.4212	 -0.7019 to -0.1405	 ****	 <0.0001	
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Table	15	 	 	 PCR	positive	results	of	OS	markers 
hMSC-3d-con vs. 
hMSC-3d-OSOSnano	 -0.7119	 -0.9926 to -0.4312	 ****	 <0.0001	
hMSC-3d-con vs. 
hMSC-3d-OS150k	 -0.6258	 -0.9065 to -0.3451	 ****	 <0.0001	
hMSC-3d-OS vs. 
hMSC-3d-OSnano	 -0.2907	 -0.5714 to -0.009991	 *	 0.0348	
hMSC-3d-OS vs. 
hMSC-7d-OS	 -0.5993	 -0.88 to -0.3186	 ****	 <0.0001	
hMSC-3d-OSnano vs. 
hMSC-7d-OSnano	 -0.6076	 -0.8883 to -0.327	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-7d-OS150k	 -0.6191	 -0.8998 to -0.3384	 ****	 <0.0001	
hMSCVII-7d-con vs. 
hMSCVII-7d-os	 -0.9495	 -1.23 to -0.6688	 ****	 <0.0001	
hMSCVII-7d-con vs. 
hMSCVII-7d-OSnano	 -1.249	 -1.529 to -0.9678	 ****	 <0.0001	
hMSCVII-7d-con vs. 
hMSCVII-7d-OS150k	 -1.174	 -1.455 to -0.8932	 ****	 <0.0001	
hMSC-7d-OS vs. 
hMSC-7d-OSnano	 -0.299	 -0.5797 to -0.01833	 *	 0.0254	
hMSC-7d-OS vs. 
hMSC-21d-OS	 0.8622	 0.5483 to 1.176	 ****	 <0.0001	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 0.8036	 0.4898 to 1.117	 ****	 <0.0001	
hMSC-7d-OS150k vs. 
hMSC-21d-OS150k	 0.3211	 0.007269 to 0.6349	 *	 0.0396	
hMSC-21d-con vs. 
hMSC-21d-OS150k	 -0.7011	 -1.045 to -0.3573	 ****	 <0.0001	
hMSC-21d-OS vs. 
hMSC-21d-OSnano	 -0.3576	 -0.7013 to -0.01378	 *	 0.0332	
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Table	15	 	 	 PCR	positive	results	of	OS	markers 
hMSC-21d-OS vs. 
hMSC-21d-OS150k	 -0.7654	 -1.109 to -0.4217	 ****	 <0.0001	
hMSC-21d-OSnano vs. 
hMSC-21d-OS150k	 -0.4079	 -0.7516 to -0.06411	 **	 0.0063	
PDL-3d-OS vs. PDL-21d-OS	 -1.049	 -1.429 to 
-0.6704	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-21d-OSnano	 -1.752	 -2.131 to -1.373	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-21d-OS150k	 -1.793	 -2.172 to -1.414	 ****	 <0.0001	
PDL-7d-OS vs. PDL-21d-OS	 -1.072	 -1.451 to 
-0.6932	 ****	 <0.0001	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 -1.774	 -2.153 to -1.395	 ****	 <0.0001	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 -1.813	 -2.192 to -1.433	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OS	 -0.7852	 -1.2 to -0.37	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OSnano	 -1.488	 -1.903 to -1.072	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OS150k	 -1.529	 -1.945 to -1.114	 ****	 <0.0001	
PDL-21d-OS vs. 
PDL-21d-OSnano	 -0.7023	 -1.117 to -0.2871	 ****	 <0.0001	
PDL-21d-OS vs. 
PDL-21d-OS150k	 -0.7442	 -1.159 to -0.329	 ****	 <0.0001	
BSP	 hMSC-3d-OS vs. 
hMSC-7d-OS	 -0.009754	 -0.01882 to -0.000692	 *	 0.0225	
hMSC-3d-OS vs. 
hMSC-21d-OS	 0.01297	 0.002986 to 0.02296	 **	 0.0015	
	 116	
Table	15	 	 	 PCR	positive	results	of	OS	markers 
hMSC-3d-OSnano vs. 
hMSC-21d-OSnano	 0.01323	 0.003128 to 0.02333	 **	 0.0013	
hMSC-3d-OS150k vs. 
hMSC-7d-OS150k	 -0.01876	 -0.02813 to -0.009391	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-21d-OS150k	 0.01152	 0.001533 to 0.02151	 **	 0.0093	
hMSC-7d-con vs. 
hMSC-21d-con	 0.01268	 0.002697 to 0.02267	 **	 0.0022	
hMSC-7d-OS vs. 
hMSC-21d-OS	 0.02273	 0.01262 to 0.03283	 ****	 <0.0001	
hMSC-7d-OSnano vs. 
hMSC-7d-OS150k	 -0.01466	 -0.02403 to -0.005297	 ****	 <0.0001	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 0.01658	 0.006594 to 0.02657	 ****	 <0.0001	
hMSC-7d-OS150k vs. 
hMSC-21d-OS150k	 0.03028	 0.0199 to 0.04066	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-7d-OSnano	 -0.06066	 -0.1095 to -0.01181	 **	 0.0031	
PDL-7d-OS vs. PDL-21d-OS	 0.06611	 0.01151 to 
0.1207	 **	 0.0046	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 0.09944	 0.04483 to 0.154	 ****	 <0.0001	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 0.08881	 0.0342 to 0.1434	 ****	 <0.0001	
COLL
A1	 hMSC-3d-con vs. hMSC-3d-OSnano	 -67.54	 -129.1 to -6.008	 *	 0.0178	
hMSC-3d-OS vs. 
hMSC-3d-OSnano	 -81.49	 -143 to -19.96	 **	 0.001	
hMSC-3d-OS vs. 
hMSC-21d-OS	 137.9	 69.08 to 206.7	 ****	 <0.0001	
hMSC-3d-OSnano vs. 
hMSC-7d-OSnano	 88.07	 26.54 to 149.6	 ***	 0.0002	
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Table	15	 	 	 PCR	positive	results	of	OS	markers 
hMSC-3d-OSnano vs. 
hMSC-21d-OSnano	 219.9	 151.1 to 288.7	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-21d-OS150k	 177.8	 109 to 246.6	 ****	 <0.0001	
hMSC-7d-con vs. 
hMSC-21d-con	 77.48	 8.691 to 146.3	 *	 0.0128	
hMSC-7d-OS vs. 
hMSC-21d-OS	 142	 73.21 to 210.8	 ****	 <0.0001	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 131.8	 63.02 to 200.6	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OS	 83.18	 7.819 to 158.5	 *	 0.0166	
hMSC-21d-con vs. 
hMSC-21d-OSnano	 83.71	 8.348 to 159.1	 *	 0.0153	
hMSC-21d-con vs. 
hMSC-21d-OS150k	 83.12	 7.763 to 158.5	 *	 0.0167	
PDL-3d-con vs. PDL-21d-con	 -53.58	 -75.08 to 
-32.07	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-21d-OSnano	 -39.52	 -61.33 to -17.72	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-21d-OS150k	 -66.98	 -87.96 to -45.99	 ****	 <0.0001	
PDL-7d-con vs. PDL-21d-con	 -50.65	 -71.64 to 
-29.66	 ****	 <0.0001	
PDL-7d-OSnano vs. 
PDL-21dOS-nano	 -46.42	 -67.92 to -24.91	 ****	 <0.0001	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 -71.58	 -93.39 to -49.77	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OS	 45.05	 22.07 to 68.04	 ****	 <0.0001	
PDL-21d-OS vs. 
PDL-21d-OSnano	 -27.51	 -50.49 to -4.516	 **	 0.0056	
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Table	15	 	 	 PCR	positive	results	of	OS	markers 
PDL-21d-OS vs. 
PDL-21d-OS150k	 -53.7	 -76.68 to -30.71	 ****	 <0.0001	
PDL-21d-OSnano vs. 
PDL-21d-OS150k	 -26.19	 -49.18 to -3.201	 *	 0.0111	
OCN	 hMSC-3d-con vs. 
hMSC-21d-con	 0.1165	 0.06398 to 0.169	 ****	 <0.0001	
hMSC-3d-OS vs. 
hMSC-3d-OSnano	 -0.0599	 -0.1069 to -0.01291	 **	 0.002	
hMSC-3d-OSnano vs. 
hMSC-21dOS-nano	 0.1086	 0.05607 to 0.1611	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-21d-OS150k	 0.05892	 0.006385 to 0.1115	 *	 0.0136	
hMSC-7d-con vs. 
hMSC-21d-con	 0.1422	 0.08968 to 0.1947	 ****	 <0.0001	
hMSC-7d-OS vs. 
hMSC-7d-OSnano	 -0.05842	 -0.1054 to -0.01143	 **	 0.0031	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 0.1211	 0.06858 to 0.1736	 ****	 <0.0001	
hMSC-7d-OS150k vs. 
hMSC-21d-OS150k	 0.07555	 0.02302 to 0.1281	 ***	 0.0002	
PDL-3d-con vs. PDL-21d-con	 -0.0405
7	 -0.0619 to -0.01925	 ****	 <0.0001	
PDL-3d-OS vs. PDL-7d-OS	 -0.0498	 -0.06842 to 
-0.03119	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-7d-OSnano	 -0.03744	 -0.05606 to -0.01883	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-7d-OS150k	 -0.02814	 -0.04676 to -0.009527	 ****	 <0.0001	
PDL-7d-con vs. PDL-7d-OS	 -0.0372
7	 -0.05646 to -0.01808	 ****	 <0.0001	
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Table	15	 	 	 PCR	positive	results	of	OS	markers 
PDL-7d-con vs. PDL-21d-con	 -0.0306
7	 -0.05199 to -0.009339	 ***	 0.0002	
PDL-7d-OS vs. 
PDL-7d-OS150k	 0.01979	 0.001174 to 0.03841	 *	 0.026	
PDL-7d-OS vs. PDL-21d-OS	 0.03669	 0.01588 to 
0.05751	 ****	 <0.0001	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 0.03007	 0.009251 to 0.05088	 ***	 0.0002	
PDL-21d-con vs. 
PDL-21d-OS	 0.03009	 0.007291 to 0.05289	 **	 0.0011	
PDL-21d-con vs. 
PDL-21d-OSnano	 0.04168	 0.01887 to 0.06448	 ****	 <0.0001	
PDL-21d-con vs. 
PDL-21d-OS150k	 0.03282	 0.01002 to 0.05562	 ***	 0.0002	
 
 
 
 
 
 
 
 
 Table	16	 	 	 PCR	positive	results	of	cementogenic	and	ligamentogenic	markers 
Tukey's multiple comparisons test	 Mean 
Diff.	 95.00% CI of diff.	 Significance	 P Value	
CAP	 hMSC-3d-con vs. 
hMSC-3d-os	 -1.258	 -2.256 to -0.2596	 **	 0.0025	
hMSC-3d-OS vs. 
hMSC-3d-OS150k	 1.255	 0.2567 to 2.253	 **	 0.0026	
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Table	16	 	 	 PCR	positive	results	of	cementogenic	and	ligamentogenic	markers 
hMSC-3d-OS150k vs. 
hMSC-7d-OS150k	 -1.345	 -2.343 to -0.3474	 ***	 0.0008	
hMSCVII-7d-con vs. 
hMSCVII-7d-OS150k	 -1.806	 -2.852 to -0.7589	 ****	 <0.0001	
hMSC-7d-OS vs. 
hMSC-21d-OS	 -1.516	 -2.645 to -0.3872	 ***	 0.0008	
hMSC-21d-con vs. 
hMSC-21d-OS	 -2.731	 -3.981 to -1.482	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OSnano	 -1.543	 -2.793 to -0.293	 **	 0.0035	
hMSC-21d-con vs. 
hMSC-21d-OS150k	 -1.734	 -2.984 to -0.4846	 ***	 0.0004	
PDL-3d-con vs. PDL-3d-OS	 3.12	 0.5842 to 
5.655	 **	 0.0036	
PDL-3d-con vs. 
PDL-3d-OSnano	 3.787	 1.252 to 6.322	 ****	 <0.0001	
PDL-3d-con vs. 
PDL-3d-OS150k	 4.092	 1.557 to 6.628	 ****	 <0.0001	
PDL-3d-con vs. PDL-7d-con	 -6.327	 -8.903 to 
-3.751	 ****	 <0.0001	
PDL-3d-con vs. 
PDL-21d-con	 3.31	 0.5164 to 6.104	 **	 0.0064	
PDL-3d-OS vs. PDL-7d-OS	 -11.22	 -13.76 to 
-8.688	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-7d-OSnano	 -8.215	 -10.83 to -5.604	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-7d-OS150k	 -11.56	 -14.13 to -8.985	 ****	 <0.0001	
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Table	16	 	 	 PCR	positive	results	of	cementogenic	and	ligamentogenic	markers 
PDL-7d-con vs. 
PDL-21d-con	 9.637	 6.774 to 12.5	 ****	 <0.0001	
PDL-7d-OS vs. 
PDL-7d-OSnano	 3.676	 1.1 to 6.252	 ***	 0.0002	
PDL-7d-OSnano vs. 
PDL-7d-OS150k	 -3.036	 -5.647 to -0.425	 **	 0.0084	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 10.61	 7.744 to 13.47	 ****	 <0.0001	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 13.55	 10.65 to 16.45	 ****	 <0.0001	
CEM
P1	 hMSC-3d-con vs. hMSC-21d-con	 0.1304	 0.04575 to 0.2151	 ****	 <0.0001	
hMSC-3d-OS vs. 
hMSC-7d-OS	 -0.07987	 -0.1556 to -0.004155	 *	 0.0284	
hMSC-3d-OS vs. 
hMSC-21d-OS	 -0.3851	 -0.4698 to -0.3005	 ****	 <0.0001	
hMSC-3d-OSnano vs. 
hMSC-21d-OSnano	 -0.1626	 -0.2472 to -0.07793	 ****	 <0.0001	
hMSCVII-7d-con vs. 
hMSCVII-7d-OS	 -0.156	 -0.2318 to -0.08031	 ****	 <0.0001	
hMSCVII-7d-con vs. 
hMSCVII-7d-OS150k	 -0.1219	 -0.1976 to -0.04616	 ****	 <0.0001	
hMSC-3d-OS150k vs. 
hMSC-21d-OS150k	 -0.2672	 -0.3519 to -0.1826	 ****	 <0.0001	
hMSC-7d-con vs. 
hMSC-21d-con	 0.08651	 0.001851 to 0.1712	 *	 0.0401	
hMSC-7d-OS vs. 
hMSC-7d-OSnano	 0.1234	 0.04772 to 0.1992	 ****	 <0.0001	
hMSC-7d-OS vs. 
hMSC-21d-OS	 -0.3053	 -0.3899 to -0.2206	 ****	 <0.0001	
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Table	16	 	 	 PCR	positive	results	of	cementogenic	and	ligamentogenic	markers 
hMSC-7d-OSnano vs. 
hMSC-7d-OS150k	 -0.08928	 -0.165 to -0.01356	 **	 0.0069	
hMSC-7d-OSnano vs. 
hMSC-21d-OSnano	 -0.2351	 -0.3198 to -0.1505	 ****	 <0.0001	
hMSC-7d-OS150k vs. 
hMSC-21d-OS150k	 -0.2271	 -0.3118 to -0.1424	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OS	 -0.5478	 -0.6405 to -0.4551	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OSnano	 -0.3542	 -0.447 to -0.2615	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OS150k	 -0.4355	 -0.5282 to -0.3427	 ****	 <0.0001	
hMSC-21d-OS vs. 
hMSC-21d-OSnano	 0.1936	 0.1008 to 0.2863	 ****	 <0.0001	
hMSC-21d-OS vs. 
hMSC-21d-OS150k	 0.1123	 0.01958 to 0.2051	 **	 0.0046	
PDL-3d-con vs. PDL-7d-con	 -1.043	 -1.523 to 
-0.563	 ****	 <0.0001	
PDL-3d-OS vs. PDL-7d-OS	 -1.537	 -2.017 to 
-1.057	 ****	 <0.0001	
PDL-3d-OSnano vs. 
PDL-7d-OSnano	 -0.7288	 -1.216 to -0.242	 ****	 <0.0001	
PDL-3d-OS150k vs. 
PDL-7d-OS150k	 -1.261	 -1.75 to -0.7725	 ****	 <0.0001	
PDL-7d-con vs. 
PDL-7d-OSnano	 0.6718	 0.1992 to 1.145	 ***	 0.0003	
PDL-7d-con vs. 
PDL-21d-con	 1.22	 0.6993 to 1.741	 ****	 <0.0001	
PDL-7d-OS vs. 
PDL-7d-OSnano	 1.007	 0.5204 to 1.494	 ****	 <0.0001	
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Table	16	 	 	 PCR	positive	results	of	cementogenic	and	ligamentogenic	markers 
PDL-7d-OS vs. 
PDL-7d-OS150k	 0.5506	 0.0483 to 1.053	 *	 0.0181	
PDL-7d-OS vs. 
PDL-21d-OS	 1.794	 1.26 to 2.327	 ****	 <0.0001	
PDL-7d-OSnano vs. 
PDL-21d-OSnano	 0.6848	 0.1579 to 1.212	 **	 0.0015	
PDL-7d-OS150k vs. 
PDL-21d-OS150k	 1.254	 0.7125 to 1.795	 ****	 <0.0001	
SCX	 hMSC-0d vs. hMSC-3d-con	 -0.04928	 -0.09324 to 
-0.005315	 *	 0.0137	
hMSC-3d-con vs. 
hMSC-3d-OSnano	 0.04288	 0.002984 to 0.08277	 *	 0.0229	
hMSC-3d-con vs. 
hMSC-7d-con	 0.05382	 0.01329 to 0.09435	 **	 0.001	
hMSC-3d-con vs. 
hMSC-21d-con	 0.07535	 0.03139 to 0.1193	 ****	 <0.0001	
hMSC-21d-con vs. 
hMSC-21d-OS	 -0.04872	 -0.09687 to -0.0005608	 *	 0.0445	
 
 
 
 
 
 
 
 
   Table	17	 	 	 One-way	ANOVA	of	groups	at	day	3,	7	and	21 Sample P value	 P value summary	
ALP	 hMSC-ALP 3d	 <0.0001	 ****	
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Table	17	 	 	 One-way	ANOVA	of	groups	at	day	3,	7	and	21 
hMSC-ALP 7d	 <0.0001	 ****	
hMSC-ALP 21d	 <0.0001	 ****	
PDL-ALP 3d	 0.0299	 *	
PDL-ALP 7d	 <0.0001	 ****	
PDL-ALP 21d	 <0.0001	 ****	
BSP	
hMSC-BSP 3d	 0.1995	 ns	
hMSC-BSP 7d	 0.0039	 **	
hMSC-BSP 21d	 0.7851	 ns	
PDL-BSP 3d	 0.9097	 ns	
PDL-BSP 7d	 0.373	 ns	
PDL-BSP 21d	 0.0002	 ***	
COL1A1	
hMSC-COL1A1 3d	 0.0095	 **	
hMSC-COL1A17d	 0.2459	 ns	
hMSC-COL1A1 21d	 <0.0001	 ****	
PDL-COL1A1 3d	 0.0007	 ***	
PDL-COL1A1 7d	 <0.0001	 ****	
PDL-COL1A1 21d	 0.0016	 **	
OCN	
hMSC-OCN 3d	 0.0051	 **	
hMSC-OCN 7d	 0.0088	 **	
hMSC-OCN 21d	 <0.0001	 ****	
PDL-OCN 3d	 0.2154	 ns	
PDL-OCN 7d	 <0.0001	 ****	
PDL-OCN 21d	 0.0009	 ***	
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Table	17	 	 	 One-way	ANOVA	of	groups	at	day	3,	7	and	21 
SCX	
hMSC-SCX 3d	 0.0087	 **	
hMSC-SCX 7d	 0.3899	 ns	
hMSC-SCX 21d	 <0.0001	 ****	
PDL-SCX 3d	 0.5003	 ns	
PDL-SCX 7d	 0.2043	 ns	
PDL-SCX 21d	 0.0021	 **	
CD44	
hMSC-CD44 3d	 0.0335	 *	
hMSC-CD44 7d	 0.3771	 ns	
hMSC-CD44 21d	 <0.0001	 ****	
PDL-CD44 3d	 <0.0001	 ****	
PDL-CD44 7d	 0.0009	 ***	
PDL-CD44 21d	 <0.0001	 ****	
CD168	
hMSC-CD168 3d	 0.093	 ns	
hMSC-CD168 7d	 0.0251	 *	
hMSC-CD168 21d	 <0.0001	 ****	
PDL-CD168 3d	 <0.0001	 ****	
PDL-CD168 7d	 0.0009	 ***	
PDL-CD168 21d	 0.3	 ns	
TLR4	
hMSC-TLR4 3d	 0.0003	 ***	
hMSC-TLR4 7d	 0.0244	 *	
hMSC-TLR4 21d	 <0.0001	 ****	
PDL-TLR4 3d	 <0.0001	 ****	
PDL-TLR4 7d	 <0.0001	 ****	
PDL-TLR4 21d	 <0.0001	 ****	
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Table	17	 	 	 One-way	ANOVA	of	groups	at	day	3,	7	and	21 
CAP	
hMSC-CAP 3d	 <0.0001	 ****	
hMSC-CAP 7d	 0.0002	 ***	
hMSC-CAP 21d	 <0.0001	 ****	
PDL-CAP 3d	 <0.0001	 ****	
PDL-CAP 7d	 0.014	 *	
PDL-CAP 21d	 <0.0001	 ****	
CEMP1	
hMSC-CEMP1 3d	 0.0653	 ns	
hMSC-CEMP1 7d	 <0.0001	 ****	
hMSC-CEMP1 21d	 <0.0001	 ****	
PDL-CEMP1 3d	 0.0002	 ***	
PDL-CEMP1 7d	 0.0003	 ***	
PDL-CEMP1 21d	 <0.0001	 ****	
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